Hematologic disorder
MONDO:0005570A disease involving the hematopoietic system.
Also known as: blood disease, blood disorder, disease of hematopoietic system, disease of the blood and blood-forming organs, disease or disorder of haematopoietic system, disease or disorder of hematopoietic system, disorder of haematopoietic system, disorder of hematopoietic system
8503 clinical trials for this condition and its sub-types, 174 tagged with Hematologic disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hematologic disorder
-
Hematopoietic and lymphoid system neoplasm 692 trials · 6,319 incl. sub-types
9 sub-types
- Hematopoietic and lymphoid cell neoplasm 484 trials · 5,928 incl. sub-types Sub-types →
- Lymphoid hemopathy 0 trials · 4,275 incl. sub-types Sub-types →
- Myeloid hemopathy 0 trials · 1,762 incl. sub-types Sub-types →
- Bone marrow neoplasm 3 trials · 1,631 incl. sub-types Sub-types →
- Thymus neoplasm 5 trials · 240 incl. sub-types Sub-types →
- Spleen neoplasm 0 trials · 232 incl. sub-types Sub-types →
- Lymph node neoplasm 5 trials · 59 incl. sub-types Sub-types →
- STAT3-related early-onset multisystem autoimmune disease 2 trials
- Cavernous hemangioma 1 trial Sub-types →
-
Leukocyte disorder 6 trials · 3,572 incl. sub-types
23 sub-types
- B-cell neoplasm 304 trials · 3,167 incl. sub-types Sub-types →
- T-cell leukemia 9 trials · 137 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 85 incl. sub-types Sub-types →
- Leukopenia 6 trials · 78 incl. sub-types Sub-types →
- Dendritic cell sarcoma 0 trials · 53 incl. sub-types Sub-types →
- Eosinophil disorder 2 trials · 51 incl. sub-types Sub-types →
- Langerhans cell histiocytosis 39 trials · 40 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Mastocytosis 15 trials · 34 incl. sub-types Sub-types →
- Functional neutrophil defect 0 trials · 13 incl. sub-types Sub-types →
- Mast cell activation syndrome 8 trials · 9 incl. sub-types Sub-types →
- POEMS syndrome 8 trials
- Subcutaneous panniculitis-like T-cell lymphoma 8 trials
- EBV-positive T-cell lymphoproliferative disorder of childhood 3 trials · 7 incl. sub-types Sub-types →
- Thymoma type B 0 trials · 4 incl. sub-types Sub-types →
- Human granulocytic anaplasmosis 1 trial
- Pelger-Huet anomaly 0 trials
- Eosinophil peroxidase deficiency 0 trials
- Hereditary neutrophilia 0 trials
- Human monocytic ehrlichiosis 0 trials
- Leukostasis 0 trials
- Pituitary gland basophil adenoma 0 trials
- Small intestinal enteropathy-associated T-cell lymphoma 0 trials
-
Bone marrow disorder 18 trials · 1,761 incl. sub-types
7 sub-types
- Bone marrow neoplasm 3 trials · 1,631 incl. sub-types Sub-types →
- Polycythemia 9 trials · 99 incl. sub-types Sub-types →
- Bone marrow failure syndrome 48 trials Sub-types →
- Osteomyelitis 43 trials · 46 incl. sub-types Sub-types →
- Fanconi anemia 29 trials · 42 incl. sub-types Sub-types →
- Drachtman Weinblatt Sitarz syndrome 0 trials
- Premature ovarian failure 15 0 trials
-
Anemia 258 trials · 975 incl. sub-types
19 sub-types
- Aplastic anemia 110 trials · 411 incl. sub-types Sub-types →
- Normocytic anemia 0 trials · 180 incl. sub-types Sub-types →
- Microcytic anemia 0 trials · 130 incl. sub-types Sub-types →
- Hypochromic anemia 0 trials · 123 incl. sub-types Sub-types →
- Beta-thalassemia and related diseases 0 trials · 99 incl. sub-types Sub-types →
- Congenital anemia 0 trials · 58 incl. sub-types Sub-types →
- Anemia due to chronic disorder 34 trials
- Pure red-cell aplasia 5 trials · 24 incl. sub-types Sub-types →
- Neonatal anemia 7 trials · 23 incl. sub-types Sub-types →
- Deficiency anemia 3 trials · 16 incl. sub-types Sub-types →
- Pancytopenia 15 trials
- Anemia due to enzyme disorder 1 trial · 14 incl. sub-types Sub-types →
- Sideroblastic anemia 0 trials · 14 incl. sub-types Sub-types →
- Macrocytic anemia 0 trials · 11 incl. sub-types Sub-types →
- Hemoglobin C disease 2 trials
- Hereditary methemoglobinemia 0 trials · 1 incl. sub-types Sub-types →
- Hemoglobin D disease 0 trials
- Hemoglobin E disease 0 trials
- Hemoglobinopathy Toms River 0 trials
-
Erythrocyte disorder 7 trials · 616 incl. sub-types
2 sub-types
- Hemoglobinopathy 34 trials · 445 incl. sub-types Sub-types →
- Malaria 134 trials · 169 incl. sub-types Sub-types →
-
Blood coagulation disease 54 trials · 539 incl. sub-types
8 sub-types
- Inherited blood coagulation disorder 8 trials · 321 incl. sub-types Sub-types →
- Coagulation protein disease 13 trials · 272 incl. sub-types Sub-types →
- Thrombotic microangiopathy 26 trials · 151 incl. sub-types Sub-types →
- Thrombophilia 12 trials · 75 incl. sub-types Sub-types →
- Hemolytic-uremic syndrome 7 trials · 24 incl. sub-types Sub-types →
- Hemorrhagic disease of newborn 1 trial
- Marantic endocarditis 0 trials
- Prekallikrein deficiency 0 trials Sub-types →
-
Hemorrhagic disease 108 trials · 508 incl. sub-types
28 sub-types
- Hemophilia A 178 trials Sub-types →
- Purpura 4 trials · 117 incl. sub-types Sub-types →
- Hemophilia B 84 trials · 91 incl. sub-types Sub-types →
- Vascular hemostatic disease 62 trials · 63 incl. sub-types Sub-types →
- Hereditary von Willebrand disease 18 trials · 29 incl. sub-types Sub-types →
- Inherited bleeding disorder, platelet-type 6 trials · 26 incl. sub-types Sub-types →
- Acquired hemophilia 2 trials · 7 incl. sub-types Sub-types →
- Congenital fibrinogen deficiency 2 trials · 6 incl. sub-types Sub-types →
- Factor VII deficiency 6 trials Sub-types →
- Congenital vitamin K-dependent coagulation factors deficiency 0 trials · 4 incl. sub-types Sub-types →
- Fetal and neonatal alloimmune thrombocytopenia 4 trials Sub-types →
- Acquired von willebrand syndrome 3 trials
- Factor X deficiency 2 trials Sub-types →
- Congenital factor XII deficiency 1 trial
- Congenital plasminogen activator inhibitor type 1 deficiency 1 trial
- East Texas bleeding disorder 0 trials
- Alpha-2-plasmin inhibitor deficiency 0 trials
- Combined deficiency of factor V and factor VIII 0 trials Sub-types →
- Congenital factor V deficiency 0 trials
- Congenital factor XI deficiency 0 trials
- Congenital factor XIII deficiency 0 trials Sub-types →
- Congenital high-molecular-weight kininogen deficiency 0 trials
- Hemophilia B leyden 0 trials
- Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation 0 trials
- Inherited prekallikrein deficiency 0 trials
- Multiple sclerosis-ichthyosis-factor VIII deficiency syndrome 0 trials
- Prothrombin deficiency 0 trials Sub-types →
- Thrombomodulin-related bleeding disorder 0 trials
-
Blood platelet disease 18 trials · 369 incl. sub-types
5 sub-types
- Thrombocytopenia 74 trials · 266 incl. sub-types Sub-types →
- Thrombocytosis disease 7 trials · 71 incl. sub-types Sub-types →
- Inherited bleeding disorder, platelet-type 6 trials · 26 incl. sub-types Sub-types →
- Qualitative platelet defect 6 trials
- TPM4-related platelet disorder 0 trials
-
Splenic disorder 3 trials · 248 incl. sub-types
8 sub-types
- Spleen neoplasm 0 trials · 232 incl. sub-types Sub-types →
- Hypersplenism 12 trials
- Splenic sequestration 1 trial
- Congestive splenomegaly 0 trials Sub-types →
- Splenic abscess 0 trials
- Splenic infarction 0 trials
- Splenic tuberculosis 0 trials
- Wandering spleen 0 trials
-
Thymus gland disorder 1 trial · 240 incl. sub-types
3 sub-types
- Thymus neoplasm 5 trials · 240 incl. sub-types Sub-types →
- Ectopic thymus 0 trials
- Thymic dysplasia 0 trials
-
Autoimmune disorder of blood 0 trials · 152 incl. sub-types
2 sub-types
- Primary thrombocytopenia 27 trials · 110 incl. sub-types Sub-types →
- Autoimmune hemolytic anemia 49 trials · 72 incl. sub-types Sub-types →
-
Congenital hematological disorder 1 trial · 101 incl. sub-types
21 sub-types
- Congenital anemia 0 trials · 58 incl. sub-types Sub-types →
- Constitutional neutropenia 2 trials · 28 incl. sub-types Sub-types →
- Congenital thrombotic thrombocytopenic purpura 5 trials
- Congenital vitamin K-dependent coagulation factors deficiency 0 trials · 4 incl. sub-types Sub-types →
- GNE myopathy 3 trials
- Congenital amegakaryocytic thrombocytopenia 1 3 trials
- Leukocyte adhesion deficiency type II 2 trials
- Congenital factor XII deficiency 1 trial
- Congenital plasminogen activator inhibitor type 1 deficiency 1 trial
- Thrombocytopenia-absent radius syndrome 1 trial
- Congenital agammaglobulinemia 0 trials Sub-types →
- Congenital analbuminemia 0 trials
- Congenital factor XI deficiency 0 trials
- Congenital factor XIII deficiency 0 trials Sub-types →
- Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome 0 trials
- Congenital secondary polycythemia 0 trials Sub-types →
- Hereditary thrombocytosis with transverse limb defect 0 trials
- Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency 0 trials
- Macrothrombocytopenia-lymphedema-developmental delay-facial dysmorphism-camptodactyly syndrome 0 trials
- Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome 0 trials Sub-types →
- Sulfhemoglobinemia, congenital 0 trials
-
Monoclonal gammopathy 24 trials · 68 incl. sub-types
3 sub-types
-
Premalignant hematological system disease 3 trials · 25 incl. sub-types
2 sub-types
- Clonal hematopoiesis 10 trials · 22 incl. sub-types Sub-types →
- Atypical lymphoproliferative disorder 0 trials
-
Paraneoplastic hematological syndrome 0 trials · 9 incl. sub-types
2 sub-types
- POEMS syndrome 8 trials
- Humoral hypercalcemia of malignancy 1 trial
-
Parasitemia 5 trials
-
Blood group incompatibility 2 trials
1 sub-type
- Rh isoimmunization 0 trials
-
L-ferritin deficiency 1 trial
-
Hyperamylasemia 1 trial
-
Bloom syndrome 0 trials
-
GATA1-Related X-Linked Cytopenia 0 trials
-
Polyclonal hyperviscosity syndrome 0 trials
-
Septicemic plague 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 1654 trials in this tab.
-
Gene editing offers hope for a One-Time sickle cell cure
Cure CompletedResearchers are testing a one-time gene therapy called exa-cel for people with severe sickle cell disease. The treatment uses CRISPR-Cas9 to edit a patient's own blood stem cells, which are then infused back after chemotherapy. The trial measures whether participants remain free …
Phase 2/3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
Can a Chemo-Transplant combo rescue patients whose leukemia resists standard treatment?
Cure CompletedThis trial tests a treatment strategy for adults with acute myeloid leukemia (AML) that did not respond to standard induction chemotherapy. Participants receive clofarabine and intermediate-dose Ara-C chemotherapy, followed by a reduced-intensity allogeneic stem cell transplant u…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Softer chemo before stem cell transplant aims to cure blood cancers in frail children
Cure CompletedResearchers test a reduced-toxicity conditioning regimen before allogeneic stem cell transplant in children and young adults with blood cancers. The regimen combines fludarabine, full-dose busulfan, and anti-thymocyte globulin. The trial measures transplant-related mortality at o…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Gentler transplant prep aims to cure tough blood cancers
Cure CompletedResearchers test a reduced-intensity conditioning regimen before allogeneic stem cell transplant in adults with high-risk AML, MDS, or ALL who cannot tolerate standard intensive treatment. The regimen combines clofarabine, busulfan, and thymoglobulin. The trial measures relapse r…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Softer chemo before stem cell transplant aims to save more blood cancer patients
Cure CompletedResearchers test a gentler conditioning regimen before allogeneic stem cell transplantation in adults with blood cancers. The goal is to see if this reduced-toxicity approach lowers the risk of death within the first year after transplant. Participants receive fludarabine, busulf…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Two-Drug malaria pill combo put to the test
Cure CompletedResearchers are testing two experimental oral antimalarial drugs, cipargamin and INE963, given alone or in combination, against standard malaria treatment. The trial enrolls people aged 12 and older who have uncomplicated falciparum malaria and weigh between 35 and 90 kilograms. …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Can an immunotherapy combo boost remission in a rare lymphoma?
Cure CompletedThis phase II trial is testing whether adding the immunotherapy drug tislelizumab to a chemotherapy regimen (pegaspargase, gemcitabine, and oxaliplatin) plus radiation can improve outcomes for people with early-stage, intermediate- or high-risk extranodal NK/T-cell lymphoma. The …
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
New short-course malaria cure could save thousands
Cure CompletedThis study tested a new way to cure vivax malaria, a type of malaria that can come back. Researchers gave a high daily dose of the drug primaquine for a short time, but only after a quick test to check for a genetic condition (G6PD deficiency) that could cause serious side effect…
Sponsor: Menzies School of Health Research • Aim: Cure
Last updated Jun 27, 2026 08:11 UTC
-
Promising malaria vaccine trial launches for children in burkina faso
Vaccine CompletedThis study tests a new malaria vaccine called SUM-101 in 69 healthy children and infants aged 5 months to 5 years in Burkina Faso. The goal is to see if the vaccine is safe and triggers a strong immune response. Participants receive three doses, and some infants also receive a ra…
Phase 1 • Sponsor: European Vaccine Initiative • Aim: Vaccine
Last updated Sep 13, 2026 00:00 UTC
-
Vaccine aims to train immune system against blood cancers
Vaccine CompletedResearchers are testing a vaccine called 3D189 in adults with blood cancers such as acute leukemia, multiple myeloma, non-Hodgkin lymphoma, and higher-risk myelodysplastic syndrome. Participants must be in remission after standard treatment and unable to receive a stem cell trans…
Phase 1 • Sponsor: 3D Medicines • Aim: Vaccine
Last updated Sep 11, 2026 00:00 UTC
-
Massive malaria vaccine trial shows promise for protecting children
Vaccine CompletedThis study tested the RTS,S/AS01E malaria vaccine in nearly 78,000 young children in Sub-Saharan Africa. Researchers checked the vaccine's safety and how well it prevents malaria. The goal was to see if the vaccine can be safely used in routine immunization programs to protect ch…
Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 09:09 UTC
-
New drug shows promise for rare immune disorder in early trial
Disease control CompletedThis study tests a drug called leniolisib in 20 people with common variable immunodeficiency (CVID), a condition that weakens the immune system. All participants will receive the drug for 6 months, starting at a low dose and increasing. The main goal is to check safety and tolera…
Phase 2 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Triple drug combo targets Hard-to-Treat brain lymphoma
Disease control CompletedResearchers are testing a combination of rituximab, acalabrutinib, and durvalumab in adults with primary central nervous system lymphoma, a rare cancer that starts in the brain or spinal cord. The trial enrolls people whose disease has returned or worsened after earlier treatment…
Phase 1 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can an oral drug slow a rare thymus cancer?
Disease control CompletedResearchers are testing whether lucitanib, an oral drug, can slow the growth of advanced thymic carcinoma that has worsened after at least one round of chemotherapy. The trial enrolls adults with recurrent or metastatic thymic carcinoma. In one part, participants receive lucitani…
Phase 2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Elderly cancer patients may benefit from geriatric support
Disease control CompletedThis study looked at whether a special care plan led by a geriatrician and a nurse could improve survival and quality of life for older adults (70+) with advanced cancer. 792 patients with breast, colorectal, lung, prostate, bladder, ovarian cancer, or lymphoma took part. The app…
Sponsor: Institut Bergonié • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered donor cells take aim at returning blood cancers
Disease control CompletedThis early-phase study tested a new approach for people whose B-cell cancers (like lymphoma or leukemia) came back after a donor stem cell transplant. Researchers took white blood cells from the original donor, genetically modified them to recognize and attack cancer cells, and g…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Chemotherapy plus immunotherapy tested against rare EBV-Driven immune storm
Disease control CompletedResearchers are testing a combination of L-DEP chemotherapy (aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) and a PD-1 antibody as initial treatment for people with Epstein-Barr virus-positive lymphoma-associated hemophagocytic lymphohistiocytosis, a rare an…
Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Antibody-Guided chemotherapy aims to give relapsed leukemia patients a second shot
Disease control CompletedAdults with B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment have few options. This phase 2 trial tests whether adding epratuzumab, an antibody that attaches to the CD22 protein found on most of these leukemia cells, to standard chemothera…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Which drug cocktail best primes myeloma for transplant?
Disease control CompletedResearchers compare two three-drug combinations, VTD and VCD, as initial treatment for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. Participants receive four cycles of either combination. The trial measures how well each combination re…
Phase 3 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can an Anti-Inflammation drug make AML chemotherapy work better?
Disease control CompletedResearchers are testing whether adding tocilizumab, a drug that blocks an inflammation signal called IL-6, to standard chemotherapy helps adults with high-risk acute myeloid leukemia. Participants receive idarubicin and cytarabine, the usual induction chemotherapy, plus a single …
Phase 1 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Triple drug combo targets mantle cell lymphoma
Disease control CompletedResearchers are testing a combination of three drugs, obinutuzumab, ibrutinib, and GDC-0199, in people with mantle cell lymphoma. The trial includes patients whose cancer has come back or stopped responding to treatment, as well as those who have not yet received treatment. The g…
Phase 1/2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a new drug calm the immune System's attack on blood cells?
Disease control CompletedThis study is testing an experimental drug called povetacicept in adults with autoimmune cytopenias — conditions where the immune system mistakenly destroys blood cells, leading to low platelet counts (immune thrombocytopenia) or anemia (autoimmune hemolytic anemia and cold agglu…
Phase 1/2 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a new drug combo improve myeloma treatment for older adults?
Disease control CompletedResearchers are testing a combination of carfilzomib, melphalan, and prednisone in adults over 65 with newly diagnosed multiple myeloma. The trial first aims to find the highest dose of carfilzomib that people can tolerate without severe side effects. Then it will measure how wel…
Phase 1/2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can aHUS patients safely stop eculizumab? algorithm put to the test
Disease control CompletedAtypical hemolytic uremic syndrome (aHUS) is a rare disease that damages the kidneys by causing blood clots in small vessels. The drug eculizumab blocks the complement system and has greatly reduced kidney failure, but doctors do not know how long patients should stay on it. This…
Phase 4 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Triplet therapy aims to deepen myeloma remission around transplant
Disease control CompletedResearchers are testing whether adding the experimental drug MLN9708 to lenalidomide and dexamethasone can help adults under 66 with newly diagnosed multiple myeloma. Participants receive three cycles of the triplet, then a stem cell transplant, followed by more triplet and maint…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Dietary change may curb recurrent c. diff in cancer patients
Disease control CompletedThis study tested whether eating less fat and more fiber can reduce the chance of a repeat Clostridioides difficile infection in cancer patients. Eight participants with leukemia, lymphoma, or other cancers followed a specific diet. Researchers tracked diarrhea and measured C. di…
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a liposomal chemo combo improve outcomes before stem cell transplant?
Disease control CompletedResearchers are testing whether a liposomal chemotherapy drug called CPX-351 works better than standard chemotherapy before an allogeneic stem cell transplant in adults with higher-risk myelodysplastic syndromes (MDS) or oligoblastic acute myeloid leukemia (AML). The trial enroll…
Phase 2 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Spinal cages built to fuse bone: can they steady a slipping spine?
Disease control CompletedResearchers are studying a spinal implant called the EVOS Lumbar Interbody System, which uses PEEK-OPTIMA HA enhanced cages, in adults with degenerative disc disease or grade 1 spondylolisthesis in the lower back. The study follows participants who receive the device during spina…
Sponsor: Invibio Ltd • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Two-Drug combo aims to push CLL into deep remission
Disease control CompletedResearchers are testing whether combining ibrutinib and venetoclax can help people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial assigns participants to either a fixed course of the two drugs or a course guided by a sensitive test…
Phase 2 • Sponsor: Pharmacyclics LLC. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Kovaltry under the microscope: how does it perform in everyday care?
Disease control CompletedThis study looked at how safe and effective Kovaltry is for people with hemophilia A when used in routine medical practice. Researchers tracked 230 patients for side effects and bleeding episodes. The goal was to gather real-world information, not to test a new treatment.
Sponsor: Bayer • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for rare skin cancer: targeted antibody tested in china
Disease control CompletedThis study tests a drug called mogamulizumab in 23 Chinese adults with mycosis fungoides or Sézary syndrome, two types of skin lymphoma that have not responded to previous treatments. The drug is given as an IV infusion and aims to shrink or eliminate cancer in the skin, lymph no…
Phase 4 • Sponsor: Kyowa Kirin China Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could a stem cell drug tame rare immune disease?
Disease control CompletedThis early-phase study tests whether Mozobil, a drug already used to boost stem cells for transplants, can safely raise white blood cell counts in people with WHIMS. WHIMS is a rare genetic condition that traps infection-fighting cells in the bone marrow, leading to frequent infe…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Radioactive antibody vs stem cell transplant: which keeps lymphoma at bay?
Disease control CompletedThis phase III trial compares two consolidation treatments for people with relapsed or refractory follicular lymphoma whose cancer has shrunk after chemotherapy. Participants receive either a radioactive antibody called Zevalin or high-dose chemotherapy followed by an autologous …
Phase 3 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Once-a-Week shot aims to stop bleeds in severe hemophilia a
Disease control CompletedResearchers are testing a long-acting factor VIII-Fc fusion protein called FRSW117 in adults and adolescents with severe hemophilia A. Participants receive the injection once a week for about a year, with extra doses as needed for bleeding. The trial measures how well this schedu…
Phase 3 • Sponsor: Hangzhou Gensciences Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Quick-Clot powder could save lives in severe trauma bleeding
Disease control CompletedThis study compares two treatments to help blood clot in severely injured trauma patients who are bleeding heavily. One is a standard frozen blood product (cryoprecipitate) that takes time to thaw, and the other is a dry powder (fibrinogen concentrate) that can be given at the be…
Phase 3 • Sponsor: Australian and New Zealand Intensive Care Research Centre • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a common nerve pain drug restore brain chemistry in bipolar cannabis users?
Disease control CompletedThis study tests whether gabapentin, an FDA-approved medication, can help restore the balance of key brain chemicals (GABA and glutamate) in people with bipolar disorder who also use cannabis. Participants are randomly assigned to receive either gabapentin or a placebo for 17 day…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a Low-Dose booster keep platelets up in ITP?
Disease control CompletedResearchers test whether giving low-dose rituximab after an initial treatment can make the response last longer in adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The trial enrolls adults whose ITP has not responded well to steroi…
Phase 3 • Sponsor: Ostfold Hospital Trust • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a shorter drug combo improve outcomes for older AML patients?
Disease control CompletedResearchers are testing whether a combination of venetoclax and a three-day course of decitabine works better than the standard pairing of venetoclax and azacitidine for older or unfit adults newly diagnosed with acute myeloid leukemia. The trial enrolls 154 participants and comp…
Phase 3 • Sponsor: The Second Affiliated Hospital of Kunming Medical University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New vaccine aims to shield leukemia patients from COVID-19
Disease control CompletedThis phase 2 trial tests a new COVID-19 booster vaccine (GEO-CM04S1) in 80 people with chronic lymphocytic leukemia (CLL). The goal is to see if this vaccine triggers a stronger immune response than standard mRNA boosters. Participants will receive either the new vaccine or a sta…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could flickering lights and tones help fight Alzheimer's? major trial underway
Disease control CompletedThis study tests a device that delivers specific light and sound patterns to the brain, aiming to slow the progression of mild-to-moderate Alzheimer's disease. About 670 participants will use the device at home for an hour daily over a year, with half receiving a sham (inactive) …
Sponsor: Cognito Therapeutics, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Monthly shot could free kids with hemophilia from frequent infusions
Disease control CompletedThis study tests fitusiran, a monthly injection, in boys aged 1 to under 12 with severe hemophilia A or B who have developed inhibitors (antibodies that block standard treatment). The goal is to find the right dose to safely lower a protein called antithrombin, which helps preven…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat leukemia in younger patients
Disease control CompletedThis study tests a chemotherapy drug called CPX-351 in people under 60 with secondary acute myeloid leukemia (AML), a type of leukemia that develops after other blood disorders or cancer treatments. The goal is to see how well the drug can make the cancer disappear or improve blo…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New anemia pill for dialysis patients tested against standard shots
Disease control CompletedThis study tests a new pill, vadadustat, taken three times a week, against the usual injected medicine for anemia in people with kidney failure who are on dialysis. About 350 adults will take part to see if the pill can safely keep their red blood cell levels in a healthy range. …
Phase 3 • Sponsor: Akebia Therapeutics • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Pairing a steroid with lymphoma gel may prevent painful skin reactions
Disease control CompletedThis phase 2 trial tests whether adding triamcinolone 0.1% ointment to Valchlor gel reduces contact dermatitis, a common skin reaction, in people with early-stage cutaneous T-cell lymphoma. Participants apply Valchlor nightly, with or without the steroid up to three times daily, …
Phase 2 • Sponsor: Rochester Skin Lymphoma Medical Group, PLLC • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Asthma breakthrough? new study tests cutting back on meds with benralizumab
Disease control CompletedThis Phase 3b study is testing whether the drug benralizumab (Fasenra) can allow people with severe eosinophilic asthma to safely reduce their daily maintenance medications. About 504 participants aged 12-75 in China will try to step down from drugs like inhaled steroids or long-…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new pill boost Immunotherapy's power against advanced tumors?
Disease control CompletedThis trial tests an experimental drug called FLX475, given alone or with the immunotherapy pembrolizumab, in people with advanced cancers that have not responded to standard treatments. The study aims to find the safest dose and to see whether the combination can shrink tumors. P…
Phase 1/2 • Sponsor: RAPT Therapeutics, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Old drug, new hope: enasidenib may ease anemia in blood cancer patients
Disease control CompletedThis early-phase trial tested the drug enasidenib in 17 people with low-risk myelodysplastic syndrome or a related leukemia who had anemia and did not have a specific gene mutation. The goal was to see if the drug could safely improve red blood cell counts and reduce the need for…
Phase 1/2 • Sponsor: Tian Yi Zhang • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Which lymphoma drug combo works best? a new study aims to find out
Disease control CompletedThis study looks at how well different immunochemotherapy combinations, such as RCHOP, BR, and RCVP, work for people with small B-cell non-Hodgkin lymphoma. Researchers will track 206 adults with this type of lymphoma to see how many respond to treatment and how long they stay fr…
Sponsor: Fudan University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Three-Drug combo outsmart returning leukemia?
Disease control CompletedThis trial tests whether adding venetoclax to a standard chemotherapy pair (cytarabine and mitoxantrone) can help adults with acute myeloid leukemia that has relapsed or not responded to initial treatment. In the first phase, researchers find the highest safe dose of cytarabine w…
Phase 1/2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can catching anemia months before joint surgery speed recovery?
Disease control CompletedThis trial tests whether screening for anemia at the time a patient consents to hip or knee replacement surgery, which is usually 4 to 6 months before the operation, leads to better outcomes than the standard approach of testing only 2 to 4 weeks before surgery. About 800 adults …
Sponsor: Ottawa Hospital Research Institute • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Four-Drug cocktail tackle Hard-to-Treat myeloma spread?
Disease control CompletedThis phase 2 trial tests a combination of four drugs, selinexor, bortezomib, lenalidomide, and dexamethasone (SVRd), in people newly diagnosed with multiple myeloma whose disease has spread outside the bone marrow, called extramedullary disease. The study aims to see how well thi…
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New Short-Course malaria treatment could prevent relapses
Disease control CompletedThis study tested a new approach to treat vivax malaria, a type that can hide in the liver and come back. Researchers used a quick test to check for a genetic condition (G6PD deficiency) that can cause dangerous side effects with the standard drug primaquine. Then, they gave a hi…
Sponsor: Macfarlane Burnet Institute for Medical Research and Public Health Ltd • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can an antioxidant supplement calm sickle cell blood cells?
Disease control CompletedThis trial tests whether MitoQ, an antioxidant supplement, can improve platelet function in adults with sickle cell anemia. Platelets in sickle cell disease are often overactive, which may contribute to blood vessel damage and complications. Researchers will give 18 participants,…
Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Experimental T-Cell therapy takes aim at lymphoma
Disease control CompletedThis early-phase trial tests a new therapy for Hodgkin and non-Hodgkin lymphoma that has returned or not responded to standard treatment. Researchers take a patient's own immune cells, train them in the lab to recognize five cancer-specific proteins (tumor-associated antigens), a…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New combo drug shows promise for Tough-to-Treat hodgkin lymphoma
Disease control CompletedThis phase 2 trial tests a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard chemotherapy in people with classical Hodgkin lymphoma that has come back or stopped responding to treatment. About 200 participants will be randomly assigned to rece…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New daily pill shows promise in controlling leukemia
Disease control CompletedThis study tested a daily medication called acalabrutinib in 552 adults with chronic lymphocytic leukemia (CLL), a type of blood cancer. Participants included those newly diagnosed, those whose cancer returned, and those who had previously taken a similar drug. The goal was to se…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for rare blood disorder: crovalimab trial underway
Disease control CompletedThis study tests a new medicine, crovalimab, for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease that destroys red blood cells. It involves healthy volunteers and people with PNH to check safety and how well the drug works. The goal is to control the disease, not …
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Sickle cell drug may boost physical function, small study hopes
Disease control CompletedThis study looks at whether voxelotor, a drug that helps red blood cells stay healthy, can improve physical function in people with sickle cell disease. Six adults aged 18-65 will take the drug for 6 months and have their walking ability tested. The goal is to see if the drug hel…
Phase 2 • Sponsor: Inova Health Care Services • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a Two-Drug combo tame a rare nerve and blood disorder?
Disease control CompletedThis phase II trial tests whether the combination of lenalidomide and dexamethasone can help people with POEMS syndrome, a rare blood disorder that damages nerves and causes other symptoms. Participants receive the drug combo either before local radiation or intensive treatment, …
Phase 2 • Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new drug pair tame hodgkin lymphoma in older patients?
Disease control CompletedThis trial tests whether combining two drugs, brentuximab vedotin (Adcetris) and bendamustine (Levact), can safely and effectively treat Hodgkin lymphoma in people aged 60 to 80 who have not had prior treatment. The standard therapy, ABVD, often causes lung damage in older adults…
Phase 1/2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new injection breathe life into COPD treatment?
Disease control CompletedThis study looks at whether dupilumab, an injectable medication, can improve lung function and reduce symptoms in adults with COPD who have a specific type of inflammation. The researchers are reviewing medical records from patients who received dupilumab as part of routine care,…
Sponsor: Azienda Ospedaliera di Perugia • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Watching patients take medicine: a new way to boost sickle cell treatment?
Disease control CompletedThis study tests whether video directly observed therapy (VDOT) — where patients or caregivers use a smartphone app to record themselves taking hydroxyurea — can improve adherence in young people with sickle cell disease. Participants will use an electronic pill bottle to track t…
Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can antibiotic paste heal bone infections without IV drips?
Disease control CompletedThis study looks at whether placing an antibiotic paste directly into the infected bone during surgery can cure foot bone infections. Adults with foot osteomyelitis will receive the paste instead of six weeks of intravenous antibiotics, followed by a short course of oral antibiot…
Sponsor: Mid and South Essex NHS Foundation Trust • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a targeted drug combo outsmart brain lymphoma?
Disease control CompletedThis early-stage trial is testing whether adding the targeted drug orelabrutinib to a standard chemotherapy regimen can safely treat newly diagnosed primary central nervous system lymphoma (PCNSL), a rare type of lymphoma that starts in the brain or spinal cord. The study will en…
Phase 1 • Sponsor: Huashan Hospital • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a new drug erase the last traces of leukemia?
Disease control CompletedThis phase 2 trial is testing whether adding venetoclax, a pill taken daily for 12 months, can reduce the number of leukemia stem cells that remain in the bone marrow of people with chronic myeloid leukemia (CML) who are already in deep molecular remission on standard TKI therapy…
Phase 2 • Sponsor: Thomas Ernst, PD Dr. med. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can Mountain-Like workouts help fatty liver? small trial aims to find out
Disease control CompletedThis study tests whether aerobic exercise in simulated altitude (normobaric hypoxia) can improve body composition and metabolism in people with MASLD, a type of fatty liver disease. Twenty sedentary adults with MASLD will walk on a treadmill for 8 weeks, either in mild altitude o…
Sponsor: University of Trieste • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a pill keep blood cancer at bay after a stem cell transplant?
Disease control CompletedThis phase III trial is testing whether taking oral azacitidine as a maintenance therapy after an allogeneic stem cell transplant can help prevent relapse in people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Participants are randomly assigned to receive…
Phase 3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
Disease control CompletedThis phase III trial is testing whether adding selinexor to a standard two-drug regimen (bortezomib and dexamethasone) can help people with relapsed or refractory multiple myeloma—a blood cancer that has returned or stopped responding to treatment. About 154 adults with measurabl…
Phase 3 • Sponsor: Antengene Corporation • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can At-Home malaria pills work as well as supervised care?
Disease control CompletedThis trial compares two ways of taking the standard malaria treatment for Plasmodium vivax: one group receives chloroquine and primaquine under direct medical supervision, while the other takes the same medication at home with phone check-ins. The goal is to see if unsupervised t…
Sponsor: Jimma University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can Lab-Grown stem cells supercharge blood recovery after transplant?
Disease control CompletedThis trial tests whether stem cells grown in the lab before being returned to the body can help blood counts recover faster after a stem cell transplant for multiple myeloma. Adults aged 18 to 65 with myeloma in first response will receive their own amplified stem cells. The main…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can engineered immune cells outsmart transplant-related cancer?
Disease control CompletedThis early-phase trial tests a new type of immunotherapy for people who develop a rare blood cancer called post-transplant lymphoproliferative disease (PTLD) after a solid organ transplant. The treatment uses the patient's own immune cells (T-cells) that are engineered to resist …
Early phase 1 • Sponsor: University College, London • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a shorter TB regimen transform child care?
Disease control CompletedThis study looks at how a shorter tuberculosis (TB) treatment regimen works for children and adolescents with non-severe TB in Zambia. It involves children, caregivers, health workers, and policymakers to understand how well the regimen is accepted, followed, and feasible in real…
Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Leukemia drug holiday: study finds many can stop imatinib without relapse
Disease control CompletedThis study looked at 220 adults with chronic myeloid leukemia who had been in deep remission for at least two years while taking imatinib. Researchers wanted to see if stopping the drug would cause the cancer to come back. They found that many patients stayed in remission after s…
Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a targeted drug boost standard chemo for an aggressive lymphoma?
Disease control CompletedThis phase 2 trial is investigating whether adding the targeted drug copanlisib to the standard R-CHOP chemoimmunotherapy regimen can help people with previously untreated diffuse large B-cell lymphoma (DLBCL) live longer without their cancer progressing. The study enrolls adults…
Phase 2 • Sponsor: University Hospital Muenster • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a cancer drug's real-world performance match clinical trial results?
Disease control CompletedThis study tracks adults with relapsed or refractory multiple myeloma who are already receiving isatuximab as part of their routine care. Researchers will measure how many patients respond to treatment, how long the response lasts, and how the drug affects quality of life and sid…
Sponsor: Sanofi • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Triple threat: could three malaria drugs together beat resistance?
Disease control CompletedThis trial tests whether giving children with uncomplicated malaria a triple combination of artemisinin-based drugs works better than the standard two-drug treatment. The goal is to see if using three drugs together can delay the malaria parasite from becoming resistant. Children…
Phase 2/3 • Sponsor: Muhimbili University of Health and Allied Sciences • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Tailored hormone dosing may spare preemies from blood transfusions
Disease control CompletedThis phase 2 trial tests whether personalized dosing of epoetin alfa—a lab-made hormone that boosts red blood cell production—can reduce or eliminate the need for blood transfusions in very low birth weight premature infants with neonatal anemia. Researchers will study how the dr…
Phase 2 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a pill tame a common blood cancer in the real world?
Disease control CompletedThis study follows about 269 people with chronic lymphocytic leukemia (CLL) who are starting venetoclax, a targeted pill. Researchers will track how well the drug shrinks or controls the cancer over the first year, and how long it takes before patients need another treatment. The…
Sponsor: AbbVie • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Gentler transplant shows promise for kids with blood diseases
Disease control CompletedThis study tests a milder chemotherapy and immune-suppressing regimen before a stem cell transplant for children and young adults with non-malignant blood disorders like sickle cell disease or immune deficiencies. The goal is to safely achieve donor cell engraftment with fewer si…
Phase 2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Blood transfusion thresholds tested to save elderly surgical patients
Disease control CompletedThis study tests whether giving blood transfusions more liberally (when hemoglobin drops to 9 g/dL) versus more restrictively (when it drops to 7.5 g/dL) reduces death and serious complications like heart attack, stroke, or kidney injury in patients aged 70 and older undergoing n…
Phase 3 • Sponsor: Johann Wolfgang Goethe University Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Leukemia drug cocktail aims to boost remission in High-Risk patients
Disease control CompletedThis study tests whether adding the targeted drug venetoclax to standard chemotherapy helps more adults with acute myeloid leukemia (AML) achieve remission. It enrolls people aged 18 to 65 with intermediate- or high-risk AML who have not yet been treated. The main goal is to see …
Phase 2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a peer coach help young people take control of their chronic illness?
Disease control CompletedThis study tests whether a peer coaching program delivered by phone and text can help adolescents and young adults (ages 16–22) with chronic conditions like sickle cell disease, diabetes, or cystic fibrosis improve their self-management skills. Participants are paired with a trai…
Sponsor: Duke University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Real-World check: does bosutinib control CML safely?
Disease control CompletedThis study tracks the safety and effectiveness of bosutinib (Bosulif) in people with chronic myelogenous leukemia (CML) who are either newly diagnosed or have not responded to or tolerated prior treatments. Researchers will monitor side effects and how well the drug controls the …
Sponsor: Pfizer • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
One-shot gene therapy aims to free hemophilia patients from constant infusions
Disease control CompletedThis trial tests a gene therapy called valoctocogene roxaparvovec for people with severe hemophilia A who have developed inhibitors (antibodies that block standard treatment). The therapy uses a harmless virus to deliver a working copy of the gene for clotting factor VIII, so the…
Phase 1/2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Drug cocktail aims to tame advanced leukemia
Disease control CompletedThis phase 2 trial is testing whether combining two drugs, ponatinib and 5-azacitidine, can improve survival in people with advanced chronic myeloid leukemia (CML). The study includes adults whose CML has progressed to an accelerated phase or a more aggressive blast crisis. Parti…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Personalized dasatinib dosing aims to tame leukemia with fewer side effects
Disease control CompletedThis study tests whether adjusting the daily dose of the leukemia drug dasatinib based on a patient's blood levels can improve safety and effectiveness. Adults newly diagnosed with chronic phase chronic myeloid leukemia (CML) will receive either standard dosing or a dose tailored…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Diabetes drug could help eradicate hidden leukemia cells
Disease control CompletedThis phase 2 trial tests whether adding pioglitazone (a diabetes drug) to the standard leukemia medication imatinib can eliminate remaining cancer cells in people with chronic-phase chronic myeloid leukemia (CML). Participants must have been on imatinib for at least two years and…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug combo aims to outsmart aggressive leukemia
Disease control CompletedThis trial tests whether adding the targeted drug ponatinib to standard chemotherapy (cytarabine) can help prevent relapse in adults with a specific, high-risk genetic form of acute myeloid leukemia (FLT3-ITD AML) who are already in first remission. The study includes two age gro…
Phase 1/2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a lower dose of an old antibiotic tame Drug-Resistant TB?
Disease control CompletedThis study tests whether a low daily dose of the antibiotic linezolid, added to a personalized combination of other drugs, is safe and tolerable for people with multidrug-resistant tuberculosis (MDR-TB). Participants take either linezolid or a placebo for 16 weeks, alongside thei…
Phase 1/2 • Sponsor: Centers for Disease Control and Prevention • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Personalizing leukemia drug doses could boost treatment success
Disease control CompletedThis trial investigates whether adjusting the dose of imatinib (Gleevec) based on the drug's level in the blood can improve outcomes for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). Participants whose imatinib blood level is low after 28 days are rand…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can a website help cancer survivors live healthier? large study tests online lifestyle coaching
Disease control CompletedThis study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…
Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New program aims to keep patients on track after Infection-Related hospitalizations
Disease control CompletedThis study tested a program to help people with opioid use disorder stay on their medication after being hospitalized for serious infections like endocarditis or bone infections. Forty adults took part to see if the program was practical and helpful. The goal is to improve long-t…
Sponsor: Boston Medical Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
One infusion could beat daily pills for Post-Birth anemia
Disease control CompletedThis study tests whether a single intravenous (IV) dose of iron works better than daily oral iron pills to treat moderate anemia in new mothers. About 4,800 women who have moderate anemia 6 to 48 hours after delivery will receive either a one-time IV iron infusion plus folic acid…
Phase 3 • Sponsor: NICHD Global Network for Women's and Children's Health • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cuts chemotherapy side effect by over 60% in breast cancer patients
Disease control CompletedThis study tested whether Naderin, an immune-boosting drug, could prevent low white blood cell counts in 79 women with breast cancer receiving first-line chemotherapy. Participants either received Naderin alongside chemotherapy or chemotherapy alone. The results showed that only …
Phase 2/3 • Sponsor: MIPO Clinic • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug naderin may help patients fight infections during cancer and TB therapy
Disease control CompletedThis study tested whether adding Naderin (sodium nucleinate) to standard treatment could reduce complications in 75 patients with cancer, tuberculosis, or hepatitis C. The main group received Naderin plus standard therapy, while the control group received standard therapy alone. …
Phase 2/3 • Sponsor: MIPO Clinic • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a month of iron before knee or hip surgery cut transfusion risk?
Disease control CompletedThis trial investigates whether anemic patients scheduled for hip or knee replacement surgery benefit from taking an iron supplement (Sideremil Vita) for 30 days before the operation, compared to taking it for only 15 days. The goal is to see if the longer treatment reduces the n…
Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Home infusion for myeloma drug passes early safety check
Disease control CompletedThis pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see…
Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a pill keep AML at bay? new study tests maintenance therapy after chemo
Disease control CompletedThis study looked at whether taking oral azacitidine (Onureg) as maintenance therapy can help older adults with acute myeloid leukemia (AML) stay in remission longer after treatment with CPX-351 chemotherapy. The study included 100 patients aged 65 and older who had achieved remi…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug duo aims to tackle tough lymphoma
Disease control CompletedThis study tested whether adding ixazomib to the standard drug ibrutinib can help people with mantle cell lymphoma that has returned or not responded to prior treatment. Forty-three adults received both pills by mouth in cycles. Researchers looked for the best dose and measured h…
Phase 1/2 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug strategy may reduce blood transfusions after organ transplants
Disease control CompletedThis study looked at whether giving romiplostim, a drug that boosts platelet production, could reduce the need for platelet transfusions in patients with low platelet counts after heart or lung transplantation or use of heart/lung support devices. Researchers compared a group of …
Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail shows promise for Tough-to-Treat leukemia in seniors
Disease control CompletedThis study tested a chemotherapy drug called CPX-351 in 59 adults aged 60 to 75 with a high-risk form of acute myeloid leukemia (AML). The goal was to see how well it could put the cancer into remission. Participants received the drug through an IV, and some also had a stem cell …
Phase 2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail shows promise for tough lymphomas
Disease control CompletedThis study tested a combination of two drugs, brentuximab vedotin and bendamustine, in 65 patients with Hodgkin lymphoma or anaplastic large cell lymphoma that had come back or didn't respond to earlier treatments. The goal was to find the safest dose and see how well the drugs w…
Phase 1/2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Targeted therapy combo aims to improve survival in older leukemia patients
Disease control CompletedThis study tests whether adding the targeted drug inotuzumab ozogamicin to a milder chemotherapy regimen improves survival in adults over 55 with a specific type of acute lymphoblastic leukemia (ALL) that is Philadelphia chromosome-negative and CD22-positive. Participants receive…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma in major trial
Disease control CompletedThis phase 3 trial tests whether a personalized cell therapy called bb2121 works better than standard drug combinations for people with relapsed and refractory multiple myeloma. About 386 participants were randomly assigned to receive either bb2121 or one of several standard regi…
Phase 3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo shows promise for Tough-to-Treat blood cancer
Disease control CompletedThis study tested two drug combinations in 186 adults with multiple myeloma that came back or didn't respond after earlier treatment. One group got pomalidomide plus low-dose dexamethasone, and another got those two plus daratumumab. The goal was to see if the tumors shrank enoug…
Phase 2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Treadmill training boosts fitness in anemic women
Disease control CompletedThis study tested whether adding a structured treadmill walking program to standard iron therapy improves exercise tolerance and quality of life in young women with mild-to-moderate iron deficiency anemia. Sixty women aged 18-28 were split into two groups: one received iron suppl…
Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Blood test may shield cancer Patients' hearts from chemo damage
Disease control CompletedThis study looked at whether using a blood test (NTproBNP) to guide heart-protecting medications can safely prevent heart damage in people with breast cancer or lymphoma receiving anthracycline chemotherapy. About 108 adults participated, and researchers measured how many joined,…
Phase 1/2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Real-World data suggests asciminib may help some leukemia patients
Disease control CompletedThis study reviewed medical records of 37 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who took asciminib because other treatments stopped working or caused side effects. Researchers wanted to see how many patients achieved complete remission within th…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for elderly lymphoma patients: a gentler treatment that preserves independence
Disease control CompletedThis phase 2 trial investigates whether combining rituximab with lenalidomide works as well as standard rituximab-based chemotherapy for patients aged 75 and older with relapsed diffuse large B-cell lymphoma. The study focuses not only on controlling the cancer but also on mainta…
Phase 2 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New oxygen test could cut unnecessary blood transfusions after heart surgery
Disease control CompletedThis study tested whether measuring oxygen levels in the blood (ScvO2) can help doctors decide when to give blood transfusions to anemic patients after heart surgery. 100 patients were randomly assigned to receive transfusions based on standard guidelines or only if their ScvO2 w…
Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for rare lymphoma: lorlatinib trial targets Drug-Resistant cancers
Disease control CompletedThis phase 2 trial tested the oral drug lorlatinib in 9 people with ALK-positive anaplastic large cell lymphoma whose cancer had returned or stopped responding to previous ALK inhibitors. The main goal was to see how many patients' tumors shrank or disappeared. Researchers also t…
Phase 2 • Sponsor: University of Milano Bicocca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Engineered immune cells target tough leukemia in early trial
Disease control CompletedThis early-phase study tested a new treatment for children and young adults with a type of leukemia that came back or did not respond to standard therapy. The approach uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells carrying a protein c…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New chemo cocktail shows promise in myeloma stem cell transplants
Disease control CompletedThis phase 2 study tested a combination of two chemotherapy drugs, busulfan and melphalan, given before an autologous stem cell transplant in 78 people with newly diagnosed multiple myeloma. All participants had already received a bortezomib-based induction therapy and then took …
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-stage study tested two experimental drugs, odronextamab and cemiplimab, in 105 patients with aggressive B-cell lymphoma that had stopped responding to other treatments. The main goal was to check safety and find the best dose. Researchers also looked at how well the dr…
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
One cord blood unit may replace two in stem cell transplants for blood cancer
Disease control CompletedThis study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for PNH patients in china: eculizumab shows promise
Disease control CompletedThis study tested eculizumab in 25 adults with PNH in China who had not previously taken complement inhibitors. Participants received infusions over 62 weeks. The main goal was to see if the drug reduced LDH levels, a marker of disease activity. Results showed a decrease in LDH, …
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo shows promise for High-Risk leukemia patients
Disease control CompletedThis study tested a new treatment for adults with a high-risk form of acute promyelocytic leukemia (APL). The experimental therapy combined arsenic trioxide, ATRA, and a low dose of idarubicin, aiming to improve survival and reduce side effects compared to the standard chemothera…
Phase 3 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Protein and exercise combo tested to fight muscle loss in sick kids
Disease control CompletedThis pilot study tested whether giving critically ill children on breathing machines extra protein along with a personalized exercise program could help preserve muscle mass and improve recovery. The trial enrolled 18 children in the ICU and measured how feasible and safe the app…
Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug may offer longer-lasting bleed control for rare platelet disorder
Disease control CompletedThis lab study tested whether concizumab, a drug that blocks a natural clotting inhibitor, can improve blood clotting in people with Glanzmann thrombasthenia (GT), a rare genetic bleeding disorder. Blood samples from 20 adults with GT and healthy donors were mixed with concizumab…
Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a second-line drug help CML patients stay cancer-free without daily pills?
Disease control CompletedThis study looked at 31 adults with chronic myeloid leukemia (CML) whose cancer came back after they stopped taking imatinib. They were given nilotinib, a more powerful targeted therapy, to see if it could make their cancer undetectable again and allow them to stop treatment once…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Real-World data shows Tirabrutinib's promise for rare brain cancer
Disease control CompletedThis study looked at 24 adults in Taiwan with a rare brain lymphoma that came back or didn't respond to treatment. Researchers checked how well the drug tirabrutinib worked and what side effects occurred in everyday medical practice, not a strict research lab. The goal was to see…
Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New blood thinner may simplify stroke prevention after heart surgery
Disease control CompletedThis study tested whether a newer blood thinner, rivaroxaban (Xarelto), is as safe and effective as the older drug warfarin for preventing strokes in people who develop atrial fibrillation after heart surgery. About 100 adults who had open-heart surgery and then experienced a new…
Phase 3 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New antibody shows promise in slowing early myeloma
Disease control CompletedThis phase 2 trial tested an antibody drug called IPH2101 in 30 people with smoldering multiple myeloma, an early form of bone marrow cancer. The drug aims to boost the immune system to attack cancer cells. Researchers measured how well it controlled the disease and checked for s…
Phase 2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Old drug, new hope for rare skin cancer?
Disease control CompletedThis study tested the drug lenalidomide (Revlimid) in 19 people with a rare type of skin lymphoma called leg-type large B-cell lymphoma that had come back or not responded to initial chemotherapy. Participants took lenalidomide pills daily for 21 days, then rested for 7 days, rep…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Last hope? new combo targets myeloma that resists standard drugs
Disease control CompletedThis phase II trial tested a combination of pomalidomide and dexamethasone in 84 patients with advanced multiple myeloma whose cancer had worsened despite treatment with bortezomib and lenalidomide. The goal was to see if this drug pair could shrink tumors and control the disease…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Off-the-Shelf CAR t cells take on Hard-to-Treat myeloma
Disease control CompletedThis early-phase study tested a new type of CAR T cell therapy, called ALLO-715, made from donor cells (not the patient's own). It was given to 73 adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The goal was to check safet…
Phase 1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New transplant strategy shows promise for blood cancer relapse
Disease control CompletedThis study tested a stem cell transplant approach for adults with relapsed follicular lymphoma, a type of blood cancer. The treatment included the drug rituximab to help control the disease and prevent complications. The goal was to see if this strategy could improve survival and…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Rabbit antibodies show promise for rare bone marrow disease
Disease control CompletedThis phase 2 trial tested a combination of rabbit antithymocyte globulin (Thymoglobuline) and ciclosporin in 35 people with acquired aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal was to see if this rabbit-based immune-suppressing tre…
Phase 2 • Sponsor: European Society for Blood and Marrow Transplantation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New malaria combo shows promise in kids – could fight drug resistance
Disease control CompletedThis study tested a new two-drug combination (KAF156 plus a special form of lumefantrine) in 295 children aged 6 months to 18 years with uncomplicated malaria. The goal was to see if the treatment safely clears the parasite and prevents the infection from coming back. The approac…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Pill may replace shots for blood cancer patients, study finds
Disease control CompletedThis study tested whether an oral medication (CC-486) could help elderly patients with a serious blood disorder called myelodysplastic syndrome (MDS) maintain their improvement after initial injectable treatment. Eleven patients who had responded to injectable azacitidine switche…
Phase 2 • Sponsor: University of Florence • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a drug shorten dialysis for kids with a rare kidney disease?
Disease control CompletedThis study tested whether the drug eculizumab (Soliris) can help children with a severe kidney condition called STEC-HUS recover faster. The trial gave 100 children either eculizumab or a placebo over several weeks. The main goal was to see if the drug reduces the number of days …
Phase 3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New antibody infusion shows promise for immune deficiency patients
Disease control CompletedThis study tested a new intravenous immunoglobulin (IVIg) treatment called Kedrion IVIg 10% in 47 people with primary immunodeficiency, a condition where the immune system cannot make enough antibodies. The goal was to see if regular infusions of this antibody therapy could preve…
Phase 3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New immune combo shows promise against stubborn lymphoma
Disease control CompletedThis study tested a combination of three drugs (DPX-Survivac, low-dose cyclophosphamide, and pembrolizumab) in 25 adults with diffuse large B-cell lymphoma that had come back or not responded to previous treatments. The goal was to see if the immune system could be boosted to shr…
Phase 2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New study checks bleeding risk when CLL drug meets blood thinners
Disease control CompletedThis study observed 45 people with chronic lymphocytic leukemia (CLL) who were taking the drug acalabrutinib (Calquence) along with a direct oral anticoagulant (DOAC), a type of blood thinner. The main goal was to see how many patients had serious bleeding events while on this co…
Sponsor: iOMEDICO AG • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug duo shows promise for rare blood cancer
Disease control CompletedThis completed phase 2 study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with relapsed or refractory NK/T-cell lymphoma, a rare and aggressive blood cancer. The goal was to see if the combination could shrink tumors or stop the cancer from growing. …
Phase 2 • Sponsor: Won Seog Kim • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New antibody shows promise for rare blood cancers
Disease control CompletedThis phase 2 trial tested a drug called lacutamab (IPH4102) in 170 people with advanced T-cell lymphoma, including Sezary syndrome and mycosis fungoides. The drug is an antibody that targets a protein on cancer cells. It was given alone or with chemotherapy to see if it could shr…
Phase 2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo offers hope for aggressive lymphoma in diverse patients
Disease control CompletedThis study tracked 102 US adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who were treated with a combination of tafasitamab and lenalidomide. The goal was to see how safe and effective this treatment is, especially for racial and ethnic …
Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New COPD treatment cuts hospital returns in severe cases
Disease control CompletedThis study tested whether a drug called mepolizumab, given after a severe COPD flare-up that required hospital care, could prevent future hospital stays or death. It involved 238 adults with eosinophilic COPD (a type with high levels of certain white blood cells). Participants re…
Phase 2/3 • Sponsor: University of Leicester • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo shows promise for rare bone marrow failure
Disease control CompletedThis study tested whether adding eltrombopag to standard immunosuppressive therapy improves early recovery in patients with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. 202 participants received either standard treatment (horse a…
Phase 3 • Sponsor: European Society for Blood and Marrow Transplantation • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for kids with hard-to-treat leukemia: experimental combo shows promise
Disease control CompletedThis study tested a new combination of chemotherapy drugs for children and young adults with acute lymphoblastic leukemia (ALL) that had returned or not responded to first treatment. The goal was to find the safest dose of clofarabine when given with other medicines. Twenty parti…
Phase 1 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a cancer drug fix an irregular heartbeat?
Disease control CompletedThis study looked at whether Vidaza, a drug used for acute leukemia, could also help treat atrial fibrillation (an irregular heartbeat). The idea was that Vidaza might reverse certain DNA changes that lower the activity of a gene important for heart function. Only one person took…
Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immune booster after transplant shows promise for blood cancer patients
Disease control CompletedThis early-phase study tested whether giving specially selected donor immune cells (NK cells) soon after a stem cell transplant is safe for people with blood cancers. Seventeen patients received the cells, and researchers monitored for serious side effects within 30 days. The goa…
Phase 1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to shrink lymphoma with less radiation
Disease control CompletedThis study tested a new approach for people with early-stage follicular lymphoma, a slow-growing blood cancer. Instead of standard full-dose radiation, participants received low-dose radiation combined with the drug Obinutuzumab (Gazyvaro). The goal was to see if this combination…
Phase 2 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug cocktails show promise for multiple myeloma patients
Disease control CompletedThis study tested different combinations of cancer drugs (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) in 477 adults newly diagnosed with multiple myeloma who were eligible for a stem cell transplant. The goal was to see which combination worked best before and…
Phase 2 • Sponsor: Mario Boccadoro • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New asthma drug shows promise in real-world greek study
Disease control CompletedThis study followed 152 adults in Greece with severe eosinophilic asthma who were starting benralizumab, a medication that helps control severe asthma. Researchers measured not only standard asthma control but also quality of life, sleep, mood, and physical activity using wearabl…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—177Lu-DOTA-TATE (a radioactive therapy) and olaparib (a PARP inhibitor)—in 18 people with certain cancers like neuroendocrine tumors, thymoma, or mesothelioma that have a specific marker (somatostatin receptor). The goal wa…
Phase 1 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could arthritis drug humira ease rare skin disease?
Disease control CompletedThis Phase 2 trial tested whether Humira (adalimumab), a drug used for arthritis, can help people with Netherton syndrome, a rare genetic skin condition that causes severe inflammation, itching, and pain. Eleven patients received six injections over three months, followed by thre…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail may boost stem cell transplant success in blood cancer
Disease control CompletedThis study tested whether adding the drug bortezomib to the standard chemotherapy before a donor stem cell transplant could help people with multiple myeloma live longer without their cancer getting worse. Fifty-four adults received the new drug combo. The main goal was to see if…
Phase 2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail aims to crush myeloma early
Disease control CompletedThis phase 2 trial tested a three-drug combination (carfilzomib, lenalidomide, and dexamethasone) followed by a stem cell transplant and maintenance therapy in 46 newly diagnosed multiple myeloma patients aged 65 or younger. The goal was to see if this intensive approach could le…
Phase 2 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug combo aims to prevent leukemia return after remission
Disease control CompletedThis study tested whether a combination of two drugs, venetoclax and azacitidine, can help adults with acute myeloid leukemia (AML) stay in remission after initial chemotherapy. The goal was to find the right dose and see if it safely delays the cancer from coming back. The study…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Promising combo tackles aggressive lymphoma in large trial
Disease control CompletedThis Phase 3 trial tested whether adding tucidinostat (an oral HDAC inhibitor) to standard R-CHOP chemotherapy improves outcomes for people with newly diagnosed MYC/BCL2 double-expressor diffuse large B-cell lymphoma, an aggressive subtype. The study enrolled 423 adults who had n…
Phase 3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Heart surgery breathing study aims to cut lung failure risk
Disease control CompletedThis study tested two ways of managing breathing during heart bypass surgery to see which better prevents lung complications. Over 1,500 adults having planned heart surgery were randomly assigned to either no breathing support or gentle, low-volume breaths while on the heart-lung…
Sponsor: CMC Ambroise Paré • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a new drug combo boost transplant success in lymphoma?
Disease control CompletedThis study tested adding lenalidomide (Revlimid) to standard chemotherapy (RICE) for people with relapsed diffuse large B-cell lymphoma. The goal was to see if the combination is safe and can improve response rates, helping more patients qualify for a stem cell transplant. Only 1…
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for lymphoma patients who Can't handle standard chemo
Disease control CompletedThis study tested two different drug combinations for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who cannot take the usual strong chemotherapy. The trial compared a newer drug (inotuzumab ozogamicin) plus standard therapy against another commo…
Phase 2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Stem cell transplant vs. drugs: which works better for younger myeloma patients?
Disease control CompletedThis study looked at 700 adults up to age 65 with multiple myeloma to see if high-dose therapy with a stem cell transplant works better than standard drug therapy (lenalidomide, bortezomib, and dexamethasone). The goal was to find out which approach delays the cancer from growing…
Phase 3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can lenalidomide keep myeloma at bay after transplant?
Disease control CompletedThis phase 3 trial tested whether taking lenalidomide (Revlimid) after an autologous stem cell transplant helps people with myeloma stay in remission longer. Over 600 participants under age 65 who had no signs of progression after transplant were randomly assigned to receive lena…
Phase 3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for hard-to-treat myeloma patients?
Disease control CompletedThis study tested a drug called daratumumab combined with dexamethasone in 64 people with multiple myeloma that had stopped responding to three other treatments. The goal was to see how many patients' tumors shrank or disappeared. The treatment is not a cure, but aims to control …
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New cocktail aims to tackle tough myeloma cases
Disease control CompletedThis study tested a combination of thalidomide, bortezomib, and high-dose melphalan followed by a stem cell transplant in 29 patients with advanced multiple myeloma who had already failed one round of treatment. The goal was to find the safest dose of thalidomide and see how well…
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New Clot-Busting catheter shows promise in leg vein blockages
Disease control CompletedThis study looked at how well the JETi device works in real-world settings to remove blood clots from deep leg veins (venous thrombosis). The device uses suction and tiny water jets to break up and remove clots. In 121 patients, the device successfully cleared at least 75% of the…
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Stem cell hope for leukemia patients
Disease control CompletedThis study looked at whether a stem cell transplant can help people under 65 with untreated chronic lymphocytic leukemia (CLL) live longer without their cancer getting worse. 241 participants received either standard treatment or a transplant. The main goal was to see how long th…
Phase 3 • Sponsor: University Hospital, Caen • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can a drug combo overcome resistance in multiple myeloma?
Disease control CompletedThis study tested whether adding a drug called vorinostat to the standard combination of lenalidomide and dexamethasone could help patients whose multiple myeloma had stopped responding to lenalidomide. The trial enrolled 25 adults with relapsed or refractory multiple myeloma. Th…
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New cocktail aims to wipe out CLL early
Disease control CompletedThis phase 2 trial tested a combination of chemotherapy (FCR) plus the drug lenalidomide in 21 people with previously untreated chronic lymphocytic leukemia (CLL). The goal was to see if adding lenalidomide could help more patients achieve a complete response, meaning no signs of…
Phase 2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug combo shows promise for kids with rare immune disease
Disease control CompletedThis study tested a drug called alemtuzumab (Campath) as a first treatment for children with hemophagocytic lymphohistiocytosis (HLH), a rare and life-threatening immune disorder. The goal was to see if it could help children survive until they could receive a stem cell transplan…
Phase 1/2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Bone drug shows promise for rare mast cell disorder
Disease control CompletedThis study tested whether denosumab, a drug given as a shot every 6 months, can improve bone density in people with osteoporosis caused by systemic mastocytosis. 24 adults with the condition took part. The goal was to see if the drug strengthens bones and prevents fractures bette…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Robotic surgery spares nerves to cut digestive woes in cirrhosis
Disease control CompletedThis study tested a new robotic surgery technique that protects the vagus nerve during spleen removal and blood vessel disconnection in 60 cirrhosis patients with portal hypertension. The goal was to see if it reduces common side effects like diarrhea and delayed stomach emptying…
Sponsor: Northern Jiangsu People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New transplant approach shows promise for rare blood disorder
Disease control CompletedThis study tested a stem cell transplant from a half-matched family donor for people with severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal was to see if this approach could improve survival one year after the transplant. The tria…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Coaching lowers blood pressure in kidney patients
Disease control CompletedThis study tested whether an educational worksheet plus health coaching could help people with chronic kidney disease improve their blood pressure. 320 adults with moderate to severe kidney disease and uncontrolled high blood pressure took part. The goal was to see if the coachin…
Sponsor: University of Michigan • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy aims to shrink spleens in bone marrow cancer patients
Disease control CompletedThis study tested whether adding the experimental drug navitoclax to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. The main goal was to see if the combination could shrink an enlarged spleen by at le…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New dosing study aims to tame Drug-Resistant leukemia
Disease control CompletedThis study tested three different starting doses (45 mg, 30 mg, and 15 mg daily) of the drug ponatinib in 283 adults with chronic phase chronic myeloid leukemia (CML) that had stopped responding to other treatments or had a specific genetic mutation (T315I). The main goal was to …
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Engineered immune cells show promise against tough lymphoma
Disease control CompletedThis phase 2 study tested a single infusion of brexucabtagene autoleucel (KTE-X19), a CAR T-cell therapy, in 105 patients with relapsed or refractory mantle cell lymphoma. The treatment aims to help the body's own immune cells recognize and attack cancer. Results showed that many…
Phase 2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Last-resort leukemia combo shows early promise in tiny trial
Disease control CompletedThis early-phase study tested a combination of two drugs, venetoclax and omacetaxine, in 6 adults with acute myeloid leukemia (AML) whose cancer had stopped responding to venetoclax-based treatments. The main goal was to find the safest dose of omacetaxine when given with venetoc…
Phase 1 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can donor plasma fix clotting issues in sepsis? new study investigates
Disease control CompletedThis study tests whether a special donor plasma product called OctaplasLG can help people with septic shock who develop blood clotting problems. Sixty participants will receive either OctaplasLG or a placebo (salt water) to see if the treatment improves clotting and outcomes. The…
Sponsor: University Hospital, Strasbourg, France • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Microtransplant without immune drugs shows promise for leukemia patients too sick for standard transplant
Disease control CompletedThis early-phase trial tested a new type of stem cell transplant called a microtransplant in 25 people with myeloid blood cancers (like leukemia) who were too old or frail for a standard transplant. Unlike a regular transplant, this one used stem cells from a partially matched fa…
Phase 1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Asthma drug benralizumab put to the test in everyday life
Disease control CompletedThis study looked at how well benralizumab (Fasenra) works for people with severe eosinophilic asthma in real-world clinics across the Gulf, Latin America, and India. Researchers tracked 291 patients to see if their asthma control improved over time using a standard questionnaire…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New program aims to cut blood transfusions in heart surgery
Disease control CompletedThis study looked at ways to reduce the need for blood transfusions in patients having planned heart surgery with a heart-lung machine. The researchers tested two approaches: improving how doctors decide to give transfusions and treating low iron and anemia before and after surge…
Sponsor: Clinique Pasteur • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Gene therapy offers new hope for sickle cell patients
Disease control CompletedThis early-phase study tested a gene therapy for sickle cell disease in 6 patients aged 12-20. Doctors took the patients' own blood stem cells, added a working gene to help produce healthy red blood cells, and infused them back after chemotherapy. The goal was to see if the treat…
Phase 1/2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Head-to-Head chemo battle: which regimen works better for hodgkin lymphoma?
Disease control CompletedThis Phase 3 trial tested two chemotherapy combinations—BEGEV and GDP—in 88 adults with relapsed or refractory classical Hodgkin lymphoma. Patients received either regimen in 21-day cycles, and their response was checked with a PET scan after three cycles. Those who achieved at l…
Phase 3 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control CompletedThis study tested a therapy called bb2121, made from a patient's own immune cells that are reprogrammed to attack myeloma cells. It included over 300 people with multiple myeloma that had returned or was high-risk. The goal was to see if the treatment could shrink tumors and cont…
Phase 2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
One donor, two transplants: could this end lifelong Anti-Rejection drugs?
Disease control CompletedThis pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Village health workers cut deaths in remote indian tribes
Disease control CompletedThis large study in rural India trained village health workers to diagnose and treat common illnesses like high blood pressure, diarrhea, pneumonia, malaria, asthma, and COPD. Over 72,000 adults aged 16-60 from 80 tribal villages took part. The goal was to reduce deaths by at lea…
Phase 4 • Sponsor: MAHAN Trust • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Leukemia drug shows promise in french compassionate use study
Disease control CompletedThis study looked at how well blinatumomab works and how safe it is in 92 adults with B-cell acute lymphoblastic leukemia that had come back or was not responding to treatment. Patients received the drug through a French compassionate use program. Researchers measured survival, r…
Sponsor: Group for Research in Adult Acute Lymphoblastic Leukemia • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested whether adding zanubrutinib to obinutuzumab works better than obinutuzumab alone for adults with follicular lymphoma that returned or didn't respond to prior treatments. About 217 people took part. The main goal was to see how many patients had their tumors shri…
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo shows promise for rare thymic cancer
Disease control CompletedThis study tested a combination of two drugs, pembrolizumab and lenvatinib, in 43 people with advanced thymic carcinoma or a related thymoma that had worsened after standard chemotherapy. The goal was to see if the combination could stop or slow cancer growth. Participants receiv…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Tailored treatment shows promise for slowing early dementia
Disease control CompletedThis study tested whether a personalized treatment plan—based on each person's test results—works better than standard care for people with mild cognitive impairment or early-stage dementia. 73 adults aged 45-76 took part, receiving either the tailored plan or usual care for 9 mo…
Phase 3 • Sponsor: Alzheimer's Prevention and Reversal Project, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Stem cell transplant shows promise against rare blood cancer
Disease control CompletedThis study tested whether a stem cell transplant (using the patient's own cells) works better than standard chemotherapy for people with a high-risk form of Waldenström macroglobulinemia, a rare blood cancer. 70 patients in China took part. The goal was to see if the transplant c…
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New oral combo shows promise for rare blood cancer
Disease control CompletedThis study tested a treatment plan using thalidomide, cyclophosphamide, and dexamethasone, followed by long-term thalidomide and prednisone, in 44 adults newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see how well the oral regimen control…
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New 9-Day combo shows promise for rare bone marrow disease
Disease control CompletedThis study tested a new 9-day treatment plan for people with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. The treatment combines three drugs (rabbit antithymocyte globulin, cyclosporine, and levamisole) to suppress the immune sys…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo therapy shows promise for rare blood cancer in younger patients
Disease control CompletedThis study tested two chemotherapy regimens (EDOCH and DHAP) given one after the other, with or without the targeted drug rituximab, in 55 younger adults (65 or under) newly diagnosed with mantle cell lymphoma. The goal was to see which combination better controls the cancer and …
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Laser surgery or watchful waiting? trial seeks best care for twin syndrome
Disease control CompletedThis trial compared two approaches for twin-to-twin transfusion syndrome (TTTS) stage 1: immediate laser surgery versus careful observation. 179 pregnant women with TTTS stage 1 and favorable conditions took part. The goal was to see which strategy leads to better survival and br…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for rare blood cancer: which drug combo works best?
Disease control CompletedThis study tested two different drug combinations in 35 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see which combination better controls the disease and improves survival without progression. Participants received either rituxi…
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Low-Dose rituximab shows promise for blood disorder
Disease control CompletedThis study tested two low-dose rituximab schedules in 100 adults with immune thrombocytopenia (ITP), a condition causing low platelet counts and bleeding. The goal was to see which regimen better raises platelets and controls bleeding. Participants had failed or relapsed on stand…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for rare anemia: drug combo shows promise
Disease control CompletedThis phase 2 trial tested a combination of two drugs, bortezomib and dexamethasone, in 18 adults with acquired pure red cell aplasia whose disease did not improve or came back after first treatment. The goal was to see if the combination could safely control the condition. The st…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
PET scans could spare hodgkin patients from extra chemo
Disease control CompletedThis study tested whether using an early PET scan after two rounds of chemotherapy can help doctors choose the right treatment for people with advanced Hodgkin lymphoma. Patients whose scan showed a good response got a milder chemo, while those with less response continued strong…
Phase 3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Promising combo slows myeloma progression in Late-Stage trial
Disease control CompletedThis study tested whether adding the drug isatuximab to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with multiple myeloma that has returned or stopped responding to prior treatments. 302 adults who had already received 1 to 3 prior therapies took part…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo shows promise for Tough-to-Treat myeloma
Disease control CompletedThis study tested a combination of pomalidomide and dexamethasone in 63 patients with multiple myeloma that had returned or stopped responding to treatment, and who had specific high-risk genetic changes. The goal was to see how well the drugs controlled the disease and what side…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Promising chemo cocktail shows hope for AML patients under 60
Disease control CompletedThis study tested a three-drug chemotherapy combination (cladribine, homoharringtonine, and cytarabine) in 65 adults under 60 with newly diagnosed acute myeloid leukemia (AML). The goal was to see how well it wiped out leukemia cells and how safe it was. Results tracked complete …
Phase 2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered T-Cells take on blood cancers in early trial
Disease control CompletedThis early-phase study tested a new type of cell therapy for people with advanced B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia (CLL) that had returned or not responded to standard treatments. Researchers took patients' own immune cells (T-cells) and added a special…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New injection attacks tumors from inside out
Disease control CompletedThis early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…
Phase 1/2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in controlling Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Whole blood may be just as good as standard transfusions for trauma bleeding
Disease control CompletedThis study looked at whether giving whole blood (all blood parts together) works as well as giving separate blood parts (red cells, plasma, platelets) to people with severe bleeding from trauma. About 200 patients who needed a massive transfusion were included. The goal was to se…
Phase 3 • Sponsor: Direction Centrale du Service de Santé des Armées • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Drug combo shows promise for tough cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…
Phase 1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for myelofibrosis patients: drug combo shows promise in shrinking spleens
Disease control CompletedThis study tested a drug called navitoclax, either alone or added to the standard drug ruxolitinib, in 191 people with myelofibrosis. The main goal was to see if the treatment could shrink the spleen by at least 35% after 24 weeks. The trial also looked at whether it could reduce…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New IV iron shows promise for speedy anemia recovery after surgery
Disease control CompletedThis study tested three types of iron supplements in 187 adults who had low iron before major surgery and developed anemia after it. The goal was to see which treatment—two different IV iron formulas or oral iron pills—worked best to quickly raise hemoglobin levels. The results h…
Phase 3 • Sponsor: Prof. Dr. Frank Behrens • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo aims to keep mantle cell lymphoma in check
Disease control CompletedThis phase 2 trial tested whether adding the targeted drug obinutuzumab to standard chemotherapy (DHAP) and stem cell transplant could better control mantle cell lymphoma in 86 previously untreated patients. Participants received obinutuzumab during induction, before transplant, …
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for sickle cell patients: drug cuts painful erections
Disease control CompletedThis study tested a drug called crizanlizumab in 36 men with sickle cell disease who suffer from priapism—painful erections lasting an hour or more. The goal was to see if the drug could reduce how often these events happen. Participants received the drug by IV and reported their…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug combo shows promise for rare blood disorder
Disease control CompletedThis study tested whether adding eltrombopag (a platelet booster) to standard immune-suppressing drugs (r-ATG and cyclosporine A) helps patients with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. Thirty-six East-Asian adults and c…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New malaria test aims to catch hidden infections in pregnant women
Diagnosis CompletedMalaria in pregnancy often causes no symptoms, yet it can lead to anaemia, premature birth, and low birth weight. Standard rapid tests miss many of these quiet infections. Researchers are comparing a new high-sensitivity rapid diagnostic test with conventional tests in 930 pregna…
Sponsor: Foundation for Innovative New Diagnostics, Switzerland • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can a Finger-Prick blood test reveal hidden malaria in the placenta?
Diagnosis CompletedMalaria in pregnancy can hide in the placenta and harm both mother and baby, yet it often goes undetected. This study enrolls about 1,200 pregnant women in Africa to see whether malaria rapid diagnostic tests, blood smears, and PCR on maternal blood can accurately detect or predi…
Sponsor: Foundation for Innovative New Diagnostics, Switzerland • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can a digital assistant and quick tests stop unnecessary antibiotics for kids?
Diagnosis CompletedResearchers in Senegal are testing a new way to care for children under 15 who come to primary health clinics with fever or diarrhea. The strategy combines rapid tests for malaria, dengue, and strep A with a digital tool that suggests treatment based on symptoms and test results.…
Sponsor: Foundation for Innovative New Diagnostics, Switzerland • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Can lung ultrasound catch sickle cell chest complications earlier than X-Rays?
Diagnosis CompletedChildren with sickle cell disease who are hospitalized for painful vaso-occlusive crises can develop acute chest syndrome, a serious lung complication. Doctors usually diagnose it with a chest X-ray, but researchers want to know whether lung ultrasound works as well or better. In…
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Which scan sees hidden myeloma better: PET or MRI?
Diagnosis CompletedResearchers compare PET scans and MRI to see which imaging method detects more myeloma lesions in adults under 65 with newly diagnosed multiple myeloma. Participants receive both scans at diagnosis, after three cycles of chemotherapy, and at the end of treatment. The study also t…
Phase 3 • Sponsor: Nantes University Hospital • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Spit test could spot gum disease early
Diagnosis CompletedThis study looked at whether certain proteins in saliva can help tell the difference between healthy gums, gingivitis (mild gum inflammation), and periodontitis (serious gum disease). Researchers collected saliva from 60 people and measured three specific biomarkers. The goal is …
Sponsor: Izmir Katip Celebi University • Aim: Diagnosis
Last updated Sep 12, 2026 00:00 UTC
-
AI trained to spot dead jawbone on routine dental X-Rays
Diagnosis CompletedResearchers at Izmir Katip Celebi University are testing a deep learning model called UNet to automatically outline bone sequestra, pieces of dead jawbone, on panoramic dental X-rays. The study uses 120 anonymized X-rays with 134 marked lesions from patients who had radiotherapy,…
Sponsor: Izmir Katip Celebi University • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
Can a quick ultrasound spot a deadly lung complication in sickle cell kids?
Diagnosis CompletedThis study looks at whether a bedside ultrasound (POCUS) can help doctors quickly diagnose acute chest syndrome in children and young adults with sickle cell disease. Researchers will enroll 30 hospitalized patients aged 0-25 to see if the ultrasound is practical and reliable com…
Sponsor: Indiana University • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
Could a video call replace the Doctor's office for dementia testing?
Diagnosis CompletedThis study is testing whether a set of memory and thinking tests, usually done in person, can be given remotely over a video call. Researchers will compare results from in-person and remote versions to see if they match. If it works, it could make dementia assessments easier for …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
A simple blood draw might reveal hidden eye lymphoma
Diagnosis CompletedThis study tests whether a blood test can help doctors tell apart uveitis caused by lymphoma from other types of uveitis. Uveitis is an eye inflammation that can lead to vision loss, and in some cases it is a sign of a rare eye lymphoma that may spread to the brain. The researche…
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
AI reads MRI scans to spot brain tumors without surgery
Diagnosis CompletedThis study tests whether an artificial intelligence system called GliomaAI-Astro23 can identify a specific type of brain tumor (IDH mutant astrocytoma) from routine MRI scans. Researchers are using existing MRI data from 1,372 patients to train and evaluate the AI. If accurate, t…
Sponsor: Deep Learning Institute of Radiological Sciences • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
New fingerstick test for blood thinner monitoring put to the test
Diagnosis CompletedThis study tested how well a small, portable device (LumiraDx) measures blood clotting (INR) compared to standard lab tests. Researchers collected blood from 420 adults, some taking warfarin and some not, using both a fingerstick and a vein draw. The goal was to see if the device…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
Fingerprick test for blood thinners put to the test
Diagnosis CompletedThis study tested whether a fingerstick blood test (LumiraDx INR test) gives accurate results for people taking the blood thinner phenprocoumon. Researchers compared fingerstick results to standard lab tests in 102 adults. The goal is to see if this quick test can reliably monito…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New imaging method could speed up diagnosis of blood clotting disorders
Diagnosis CompletedThis study tested a new diagnostic tool that uses imaging flow cytometry to examine platelets in blood samples. Researchers compared it to standard lab tests in 31 patients suspected of having platelet disorders or heparin-induced thrombocytopenia. The goal was to see if the new …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New blood test could speed up Life-Saving treatment for HUS patients
Diagnosis CompletedThis study tested a new blood test designed to quickly determine whether the complement system is involved in a serious kidney condition called thrombotic microangiopathy (TMA). The test measures complement deposits on cells in a lab sample. Researchers compared test results to h…
Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New ultrasound could spot heart trouble before It's too late for chemo patients
Diagnosis CompletedThis study tested whether a special heart ultrasound (2D strain imaging) can detect early signs of heart damage caused by anthracycline chemotherapy in 100 leukemia patients. The goal is to catch problems sooner, so doctors can adjust treatment and reduce the risk of permanent he…
Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:39 UTC
-
Protein fingerprints may spot hidden transplant rejection
Diagnosis CompletedThis study tested whether analyzing proteins from kidney biopsy and urine samples can improve the diagnosis of microvascular inflammation, a key sign of antibody-mediated rejection in kidney transplant recipients. Researchers used mass spectrometry to find protein signatures in 1…
Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:38 UTC
-
New PET tracer shows promise for spotting myeloma bone lesions
Diagnosis CompletedThis study compares two types of PET/CT scans—one using a standard tracer (FDG) and another using a newer tracer (FCH)—to see which detects more bone lesions in people newly diagnosed with multiple myeloma. Twenty participants will receive both scans and an MRI within three weeks…
Phase 3 • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Blood test may spot deadly transplant complication earlier
Diagnosis CompletedThis completed study looked at whether certain proteins in the blood (called biomarkers) can help predict acute graft-versus-host disease (aGVHD) in 500 patients who had a stem cell transplant for blood cancers. Researchers measured levels of REG3, ST2, IL-6, IL-8, and TNF R ever…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
New imaging agent could sharpen detection of blood cancers
Diagnosis CompletedThis early-phase study tested a new radioactive tracer called [18F]-Fludarabine for PET scans in 10 people with untreated chronic lymphocytic leukemia or diffuse large B-cell lymphoma. The goal was to see how the tracer spreads in the body and how well it highlights cancer cells.…
Phase 1 • Sponsor: University Hospital, Caen • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
Simple quiz may reveal hidden brain struggles in sickle cell patients
Diagnosis CompletedThis study looked at whether the Montreal Cognitive Assessment (MoCA), a short test, can accurately screen for thinking and memory problems in adults with sickle cell disease. Researchers compared MoCA results to a full set of standard cognitive tests in 65 adults. The goal is to…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
Can a drug and donor cells stop leukemia from returning after transplant?
Prevention CompletedResearchers are testing whether giving azacitidine, a chemotherapy drug, together with donor lymphocyte infusions after a stem cell transplant can prevent relapse in people with high-risk acute myeloid leukemia or myelodysplastic syndrome. About 30 patients will receive the combi…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
Can a Lab-Made clotting factor outsmart blood thinners?
Prevention CompletedResearchers are testing a new drug called VMX-C001 to see if it can help blood clot normally in people who take common blood thinners. The trial gives single doses of VMX-C001 or a placebo to healthy volunteers, and also to healthy older adults who take one of three blood thinner…
Phase 1 • Sponsor: VarmX B.V. • Aim: Prevention
Last updated Sep 11, 2026 00:00 UTC
-
Can a simple preventive drug cut malaria and anemia in infants?
Prevention CompletedThis trial tests whether giving infants a preventive dose of the antimalarial drug sulfadoxine-pyrimethamine during routine health visits can lower their risk of malaria and anemia. Researchers will follow about 2,100 children in Cameroon, comparing those in areas receiving this …
Sponsor: London School of Hygiene and Tropical Medicine • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
Can scheduled malaria drugs shield infants from severe illness?
Prevention CompletedThis trial tests whether giving infants in Côte d'Ivoire a preventive dose of an antimalarial drug at routine health visits can lower their risk of malaria and anemia. Researchers will compare outcomes for infants in areas receiving this intervention against those receiving stand…
Sponsor: London School of Hygiene and Tropical Medicine • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
New malaria prevention combo tested in mali infants
Prevention CompletedThis study tests the safety of an experimental medicine called L9LS in infants aged 1 to 12 months in Mali. It also looks at how L9LS affects the immune response to a malaria vaccine called R21/Matrix-M. The goal is to find a better way to prevent malaria in young children.
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Sep 05, 2026 00:00 UTC
-
Vitamin a boost before stem cell transplant may shield the gut
Prevention CompletedThis trial tests whether a single high dose of vitamin A, given before a donor stem cell transplant, can prevent gastrointestinal graft-versus-host disease (GVHD), a condition where donor cells attack the gut. Vitamin A deficiency is linked to a higher risk of this complication, …
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
New antibiotic may replace standard infection prevention in blood cancer patients
Prevention CompletedThis study tested whether fosfomycin, an older antibiotic, works as well as ciprofloxacin for preventing serious infections in people with blood cancers like leukemia or those receiving a stem cell transplant. 177 adults from 11 Spanish hospitals took part. The main goal was to s…
Phase 3 • Sponsor: Fundación para la Investigación Biosanitaria del Principado de Asturias • Aim: Prevention
Last updated Jun 27, 2026 13:01 UTC
-
New 'Star Homes' aim to slash childhood disease in tanzania
Prevention CompletedThis study tested whether specially built houses (Star Homes) could reduce malaria, respiratory infections, and diarrhea in children under 13 in rural Tanzania. Over 1,100 children lived either in a Star Home or a traditional mud house. The Star Homes have screened windows, solar…
Sponsor: University of Oxford • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Could targeted drug dosing stamp out malaria in thai hotspots?
Prevention CompletedThis study tested whether giving antimalarial drugs to everyone in high-risk villages and forest workers could lower malaria cases in Thailand. Over 14,000 people took part. The goal was to see if this approach reduces infections from both Plasmodium falciparum and Plasmodium viv…
Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jun 27, 2026 12:25 UTC
-
Shorter blood thinner course after delivery may be safe for some women
Prevention CompletedThis study looked at 86 women with Factor V Leiden or Factor II mutations who had no history of blood clots. Researchers compared how long doctors prescribed blood thinners after childbirth (less than 2 weeks vs. 6 weeks) to see if shorter treatment was still effective at prevent…
Sponsor: Hospices Civils de Lyon • Aim: Prevention
Last updated Jun 27, 2026 12:04 UTC
-
New vaccine strategy aims to shield lymphoma patients from deadly infections
Prevention CompletedThis study tested a two-step vaccine approach to prevent pneumococcal infections in 26 adults with diffuse large B-cell lymphoma who were receiving chemotherapy with rituximab. The vaccines, Prevenar and Pneumovax, were given in a prime-boost sequence to boost immune protection. …
Phase 3 • Sponsor: University Hospital, Tours • Aim: Prevention
Last updated Jun 27, 2026 09:05 UTC
-
Diabetes drug shows promise in preventing deadly transplant complication
Prevention CompletedThis study tested whether sitagliptin, a diabetes medicine, could prevent acute graft-versus-host disease (GVHD) in 190 adults receiving stem cell transplants from related or unrelated donors. Participants took sitagliptin along with standard GVHD prevention. The main goal was to…
Phase 3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
Simple zinc pill may shield kids with sickle cell from deadly infections
Prevention CompletedThis study tested whether daily zinc supplements can lower the number of serious infections in young children with sickle cell anemia. Researchers in Uganda gave 100 children either zinc or a placebo for a period and tracked infections. The goal is to find an affordable, easy-to-…
Phase 2/3 • Sponsor: Indiana University • Aim: Prevention
Last updated Jun 27, 2026 09:00 UTC
-
Simple malaria doses during baby shots could save thousands of lives
Prevention CompletedThis large study tested giving infants up to 6 doses of a malaria preventive medicine alongside their regular vaccinations during the first two years of life. Over 94,000 children in Mozambique, Sierra Leone, and Togo took part. The goal was to see if this approach could reduce m…
Sponsor: Barcelona Institute for Global Health • Aim: Prevention
Last updated Jun 27, 2026 08:14 UTC
-
Can IV iron prevent anemia in pregnant women?
Prevention CompletedThis study tested whether giving intravenous iron to pregnant women who have low iron stores but not yet anemia can prevent them from becoming anemic and help their babies grow normally. 600 women took part. The goal is to see if a single IV dose works better than usual care.
Phase 4 • Sponsor: Services Institute of Medical Sciences, Pakistan • Aim: Prevention
Last updated Jun 27, 2026 08:11 UTC
-
Malaria vaccine plus bednets: a One-Two punch?
Prevention CompletedThis study in Malawi looks at whether giving children the RTS,S malaria vaccine along with special insecticide-treated bednets (PBO nets) can lower malaria infection and spread. About 1,700 children aged 7 months to 10 years took part. The goal is to see how well these two tools …
Sponsor: Michigan State University • Aim: Prevention
Last updated Jun 27, 2026 08:10 UTC
-
A cup of lavender tea a day may keep PMS blues away — science puts it to the test
Symptom relief CompletedThis trial tests whether drinking lavender herbal tea twice daily for nine days around each menstrual cycle can reduce the emotional and physical symptoms of premenstrual syndrome (PMS), such as anxiety, depression, stress, and pain. Sixty women with PMS will be randomly assigned…
Sponsor: Sakarya University • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can Blood-Type-Matched platelets make transfusions safer?
Symptom relief CompletedResearchers are testing a new way to prepare platelets for transfusion that matches a patient's ABO blood type. The study enrolls adults aged 18 to 65 who need platelet transfusions for blood disorders. Doctors measure platelet counts and bleeding before and after transfusion to …
Phase 4 • Sponsor: The General Hospital of Western Theater Command • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a 12-Week exercise programme build strength safely in boys with hemophilia?
Symptom relief CompletedBoys with hemophilia often miss out on games and activities because of concerns about bleeding and joint damage. Researchers developed a 12-week muscle-strengthening exercise programme with input from children, parents, and physiotherapists. The DOLPHIN-II trial compares this pro…
Sponsor: East Kent Hospitals University NHS Foundation Trust • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Spleen surgery may reshape cholesterol in cirrhosis
Symptom relief CompletedPeople with liver cirrhosis often have abnormal cholesterol and triglyceride levels. Researchers at Northern Jiangsu People's Hospital are following 150 cirrhosis patients who undergo laparoscopic splenectomy and azygoportal disconnection, a common operation for bleeding caused b…
Sponsor: Northern Jiangsu People's Hospital • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can AML patients give their own transfusions at home?
Symptom relief CompletedResearchers at Rigshospitalet in Denmark are testing whether adults newly diagnosed with acute myeloid leukemia can safely measure their own blood counts and give themselves blood and platelet transfusions at home. The study trains and certifies 22 participants to use a home bloo…
Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Iron shot boosts heart Patients' stamina, study hopes
Symptom relief CompletedThis study tests whether a single dose of intravenous iron (ferric derisomaltose) can improve exercise capacity in people with heart failure with preserved ejection fraction who also have iron deficiency. About 66 adults will receive either the iron infusion or a placebo, and the…
Phase 2/3 • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Can a phone app tame sickle cell pain and cut opioid use?
Symptom relief CompletedThis trial tests whether a smartphone app called You Cope, We Support (YCWS) can help adults with sickle cell disease better manage stress and pain, and possibly reduce opioid use. Participants will be randomly assigned to either use the app along with self-monitoring, or just se…
Sponsor: University of Florida • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Can a smartphone app ease sickle cell pain and help you sleep?
Symptom relief CompletedThis study tests whether a smartphone-based mindfulness program is practical and liked by teens and young adults (ages 15-39) with sickle cell disease who have chronic pain or sleep problems. Participants use a guided meditation app for about 8 weeks. The goal is to see if people…
Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC
-
Which mouthguard do patients prefer for jaw pain?
Symptom relief CompletedThis study looked at how satisfied people were with three different types of mouthguards (occlusal splints) for jaw joint and muscle pain (TMD). 27 adults who had jaw pain for at least 3 months and had never been treated for it tried one of the splints. The main goal was to see w…
Sponsor: Mansoura University • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
Could kids have upper limb surgery fully awake? new trial tests the idea
Symptom relief CompletedThis trial tests whether a local anesthetic injection (ropivacaine) can keep children aged 6 to 12 awake and comfortable during upper limb surgery, avoiding general anesthesia. Children watch cartoons on a tablet for distraction while the anesthetic is given. The study aims to se…
Phase 4 • Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Mediterranean diet may soothe sickle cell pain, new study hopes
Symptom relief CompletedThis study looks at whether following a Mediterranean diet can help reduce chronic pain in people with sickle cell disease. About 30 adults with sickle cell disease who have pain most days will try the diet and report their pain levels. Researchers will also check changes in gut …
Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Cartoon calm: animated film may ease Kids' surgery fears
Symptom relief CompletedThis trial investigates whether a double-reading animated film, watched by both children and their parents before surgery, can reduce anxiety in children aged 3 to 7. The film uses avatars to walk the child through their hospital journey, from room to operating room. Researchers …
Sponsor: University Hospital, Bordeaux • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Could an amino acid shorten sickle cell pain crises?
Symptom relief CompletedThis phase 3 trial tests whether intravenous arginine, an amino acid, can shorten painful episodes in children with sickle cell disease. Participants aged 3 to 21 receive either arginine or a placebo alongside standard pain treatment. The study measures how quickly the crisis res…
Phase 3 • Sponsor: Claudia R. Morris • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Gentle touch may soothe anxiety for isolated blood cancer patients
Symptom relief CompletedThis study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …
Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could an ancient herb ease Chemo's worst side effects?
Symptom relief CompletedThis study tests whether PG2, a compound from the astragalus root, can reduce fatigue and low white blood cell counts caused by chemotherapy in women with stage II or III breast cancer. Participants receive either PG2 or a placebo alongside their standard chemotherapy. The goal i…
Phase 2 • Sponsor: PhytoHealth Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Ancient remedy takes on chemo nerve damage
Symptom relief CompletedThis study tested whether roasted nux vomica capsules can help with nerve pain caused by the chemotherapy drug bortezomib in multiple myeloma patients. Twenty-two participants took the capsules for six weeks while continuing their regular chemo. Researchers measured changes in ne…
Sponsor: The First Affiliated Hospital of Zhejiang Chinese Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Exercise program shows promise for hemophilia patients
Symptom relief CompletedThis study tested whether a 6-month adapted physical activity program could improve functional capacity in people with hemophilia. Fourteen participants did exercises twice a week to improve joint mobility, strength, and balance. The main goal was to see if their walking distance…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Special PE program shows promise for building muscle in teens with intellectual disability
Symptom relief CompletedThis study tested a 10-week progressive adapted physical education program for 46 adolescents with mild intellectual disability. Half did the special program plus regular school activities, while the other half stuck to their usual curriculum. Researchers measured upper-body stre…
Sponsor: Inonu University • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Virtual forests lift mood: VR nature boosts depression treatment
Symptom relief CompletedThis study tested whether adding virtual reality (VR) nature experiences to standard treatment helps adults with mild to moderate depression feel better. 45 participants were split into three groups: one used a high-end VR lab setup, another used a simple self-managed VR, and a c…
Sponsor: Sykehuset Innlandet HF • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New web tool aims to lighten load for dementia caregivers
Symptom relief CompletedThis study tested a web platform designed for people with mild cognitive impairment or mild to moderate dementia and their primary caregivers. The platform offers social networks, activities, and games to improve quality of life and help them stay in the community longer. Researc…
Sponsor: University Hospital, Rouen • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Can lotions and gloves soothe cancer therapy's harsh side effects?
Symptom relief CompletedThis study tested a set of dermo-cosmetic products (hand/foot serum, nail strengthener, dissolving oil, and gloves/slippers) in 20 multiple myeloma patients receiving bispecific antibody therapy. The goal was to see if these natural-based products could prevent or reduce skin and…
Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Iron boost after heart valve procedure shows promise in small trial
Symptom relief CompletedThis study looked at whether a single intravenous iron dose could improve exercise capacity in people with severe aortic stenosis and iron deficiency who were scheduled for a valve replacement. About 100 participants received either iron or a placebo. The main goal was to see if …
Phase 2 • Sponsor: Oslo University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Phone calls may boost chemo success in leukemia patients
Symptom relief CompletedThis study tested whether weekly nurse phone calls could help people with chronic lymphocytic leukemia (CLL) stick to their chemotherapy plan and reduce side effects. Sixty patients were split into two groups: one received regular care, and the other also got a weekly call to che…
Sponsor: University Hospital, Toulouse • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Digital coaching eases cancer treatment struggles
Symptom relief CompletedThis study tested an online educational program for cancer patients receiving chemotherapy. The program included video sessions, peer discussions, and digital materials to help with symptom management and emotional coping. Researchers compared 212 patients who used the program to…
Sponsor: Zagazig University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Drug-Free pain relief for sickle cell disease shows promise
Symptom relief CompletedThis study tested whether guided relaxation and acupuncture can reduce chronic pain and opioid use in adults with sickle cell disease. About 360 participants across three health centers were randomly assigned to one of these therapies or usual care. The goal was to see if these m…
Phase 2 • Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Phone therapy eases cancer Survivors' distress in rural areas
Symptom relief CompletedThis study tested a stepped-care telehealth program for cancer survivors living in rural areas who experience anxiety, depression, or sleep problems. Participants received either low-intensity check-ins or high-intensity phone therapy with a licensed therapist, depending on sympt…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
New lens promises better sight at all distances for cataract patients
Symptom relief CompletedThis study tested a special type of artificial lens (TECNIS Eyhance IOL) in 62 adults aged 45-75 who had cataract surgery. The goal was to see how well the lens helps people see clearly at different distances, from close up to far away. Researchers measured vision at nine distanc…
Sponsor: Democritus University of Thrace • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
New telehealth coaching aims to ease the financial burden of cancer
Symptom relief CompletedThis study tested a telehealth program called CC LinksTele that provides one-on-one coaching to help cancer survivors and their caregivers manage financial and legal issues related to cancer care. 124 adult patients and caregivers from a pediatric cancer clinic took part. The goa…
Sponsor: Jean Edward • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Simple foot bath may ease chemo fatigue in children
Symptom relief CompletedThis study tested whether a nightly warm foot bath can reduce fatigue in children aged 7-12 with lymphoma who are undergoing chemotherapy. Sixty children took a 20-minute foot bath at 38-40°C for 7 days. The goal was to see if this simple, non-drug approach could improve their en…
Sponsor: Koç University • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Can virtual physio help kids with leukemia? small study tests hybrid approach
Symptom relief CompletedThis study tested whether a hybrid (in-person and online) physiotherapy program is feasible for children aged 4-17 with acute lymphoblastic leukemia. Ten children and their parents tried the program, which included tailored exercises and games. The goal was to see if families cou…
Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Free blood transfusions help blood cancer patients choose hospice
Symptom relief CompletedThis study looked at whether providing free blood transfusions to blood cancer patients would encourage them to enroll in hospice care earlier. Many patients delay hospice because they need transfusions for symptom relief, but hospices often cannot afford to provide them. The stu…
Sponsor: Adam Olszewski • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
New study aims to crack the code of autoimmune diseases
Knowledge-focused CompletedThis study is collecting blood, urine, and stool samples from 500 children with autoimmune diseases and healthy controls. Researchers will analyze these samples to find molecular patterns that could help diagnose these conditions and guide treatment decisions. The goal is to crea…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Dust and crops: scientists hunt for Pesticide-Leukemia link in kids
Knowledge-focused CompletedThis study looked at 629 children in California to see if exposure to pesticides at home or from nearby farms is linked to childhood leukemia. Researchers collected dust from carpets and vacuum cleaners and mapped crops near homes. The goal was to measure chemical levels and see …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Lab tests could pick the right drug for tough myeloma cases
Knowledge-focused CompletedThis study tests a new way to choose treatments for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to standard therapy. Researchers use a lab test that checks many drugs at once, along with genetic information, to find which drug or d…
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New study aims to uncover why catheters cause blood clots
Knowledge-focused CompletedThis study looks at how four types of central venous catheters (thin tubes placed in large veins) affect the body's clotting system. Researchers will take blood samples from 88 adults right after catheter insertion and again after flushing, to measure clotting changes. The goal i…
Sponsor: Thomas Kander • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists decode cancer genes to personalize treatment
Knowledge-focused CompletedThis completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists map protein patterns in lymphoma to unlock disease secrets
Knowledge-focused CompletedThis completed study analyzed leftover tissue samples from 130 people with lymphoma or related conditions. Researchers measured levels of histone and other proteins to find patterns linked to different lymphoma types. The goal was to better understand the biology of these cancers…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
NIH launches major study to unlock secrets of rare inflammatory diseases
Knowledge-focused CompletedThis study follows up to 5,000 people with autoinflammatory diseases (like NOMID, CANDLE, and juvenile dermatomyositis) and their healthy relatives. Researchers will collect medical history, blood samples, and imaging over 2-5 day visits to learn how these diseases work and find …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists track rare muscle disease to unlock its secrets
Knowledge-focused CompletedThis study followed 78 people with GNE myopathy, a rare genetic disease that causes progressive muscle weakness starting in young adulthood. Researchers collected medical history, blood samples, and muscle function tests over up to two years to understand how the disease progress…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Sickle cell patients checked for hidden lung danger
Knowledge-focused CompletedThis study measured how common pulmonary hypertension (high blood pressure in the lungs) is in adults with sickle cell anemia. Nearly 1,000 participants had heart ultrasounds and blood tests, then were contacted by phone for up to 3 years to track their health. The goal was to un…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Glow-in-the-dark dye may help surgeons spot hidden cancer in kids
Knowledge-focused CompletedThis study is testing whether a green dye called ICG can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Gait analysis sheds light on joint damage in moderate hemophilia
Knowledge-focused CompletedResearchers at Nantes University Hospital are studying how joint damage from bleeding affects walking in adults with moderate hemophilia. About 24 participants will have their gait measured with motion capture and force platforms during a single visit. The study also collects cli…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
The immune cells that could make stem cell transplants work better
Knowledge-focused CompletedResearchers are studying natural killer (NK) cells in people who receive stem cell transplants for leukemia. The study follows 92 patients and their donors, looking at genes called KIR and HLA that control how NK cells work. By tracking NK cells during immune recovery, researcher…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Scientists hunt for hidden causes of painful leg ulcers in sickle cell disease
Knowledge-focused CompletedThis completed study looked at why people with sickle cell disease develop chronic leg ulcers. Researchers collected skin swabs, blood samples, and survey data from 405 adults to explore the role of skin bacteria and environmental factors. The goal was to better understand the ca…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Pens and vouchers: can small rewards boost participation in blood cancer research?
Knowledge-focused CompletedResearchers want to learn what causes myeloproliferative neoplasms, a group of rare blood cancers. They are testing whether small incentives like pens, trolley tokens, or a £10 reimbursement encourage more people to join a case-control study. The trial includes about 100 patients…
Sponsor: Queen's University, Belfast • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Mosquito bites as a research tool: can scientists reproduce malaria infection on demand?
Knowledge-focused CompletedResearchers in Lambaréné, Gabon, want to see if they can safely and reliably infect healthy adult volunteers with malaria using bites from local Anopheles gambiae mosquitoes carrying a local strain of Plasmodium falciparum. The team raises the mosquitoes in the lab, feeds them ma…
Phase 1 • Sponsor: Centre de Recherche Médicale de Lambaréné • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Leukemia treatment showdown: which works best?
Knowledge-focused CompletedThis registry study follows 400 patients with a specific type of leukemia (non-high-risk APL) who are 70 or younger. It compares two standard treatments: ATRA plus chemotherapy versus ATRA plus arsenic trioxide. The goal is to see which approach leads to better long-term outcomes…
Sponsor: Groupe Francophone des Myelodysplasies • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Neighborhood chats may help overcome COVID-19 testing mistrust
Knowledge-focused CompletedThis study tested whether weekly community-led group discussions about health topics could change how people feel about COVID-19 testing and vaccines. 49 adults from housing authority agencies took part in Zoom meetings and completed surveys over 18 weeks. The goal was to see if …
Sponsor: Old Dominion University • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
PET scans may reveal hidden leukemia spots before CAR t treatment
Knowledge-focused CompletedThis pilot study tested whether PET-CT scans can detect leukemia that has spread outside the bone marrow in patients with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (ALL). Ten participants received a PET scan before and after CAR T-cell therapy. The goal was to…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Scientists probe COVID-19's attack on immune cells
Knowledge-focused CompletedThis study looked at how the virus that causes COVID-19 reduces the number of infection-fighting white blood cells (lymphocytes) in the blood. Researchers collected blood samples and medical records from 240 adults with or recovering from COVID-19. The goal was to learn more abou…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Real-World data may reveal which ITP treatments work best
Knowledge-focused CompletedThis study looks back at health records from over 3,700 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys blood platelets, raising bleeding risk. Researchers want to see which second-line treatments doctors prescribe after first-line steroids…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Preterm Kids' brains tracked to age 9 in new study
Knowledge-focused CompletedThis study follows children born moderately or late preterm (32-36 weeks) to age 9, measuring their thinking, movement, language, behavior, and growth. Researchers compare these kids to full-term peers to understand long-term effects. The goal is to learn how early development pr…
Sponsor: Noordwest Ziekenhuisgroep • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Can these supplements boost nutrient absorption in chronic illness?
Knowledge-focused CompletedThis study is testing whether two dietary supplements, Goodphyte IB Defense and Goodphyte Immunity, are acceptable and easy for adults with chronic diseases like IBD, hypertension, anemia, or multiple sclerosis to take. Researchers will also check if the supplements improve how w…
Sponsor: University of Thessaly • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
New document helps young adults voice End-of-Life wishes
Knowledge-focused CompletedThis study tested a document called Voicing My CHOiCES, designed to help young adults (ages 18-39) with serious illnesses like cancer or HIV discuss their care preferences. Participants filled out questionnaires about anxiety, social support, and communication, then reviewed the …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Can a simple blood test predict surgery risks?
Knowledge-focused CompletedThis study asks whether having anemia before major gastrointestinal surgery leads to more complications afterward. Researchers will follow 146 adults in Greece who undergo open or laparoscopic GI surgery, tracking any complications until discharge or day 8 after surgery. They wil…
Sponsor: University of Ioannina • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Does seeing a doctor shake your trust in AI? new study investigates
Knowledge-focused CompletedThis study tracks 180 orthopedic patients in Cyprus to see if a single doctor visit changes how much they trust AI health information. Patients fill out surveys before and after their appointment, and doctors also report on the accuracy of any AI advice patients brought up. The g…
Sponsor: Utku Gürhan • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can we predict lung damage from CAR t-cell therapy?
Knowledge-focused CompletedThis study looks back at the medical records of about 266 adults who received CAR T-cell therapy for blood cancers. The goal is to describe lung complications that happen within 30 days or up to 2 years after treatment. Researchers will also look for patient characteristics that …
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Scientists hunt for allergy genes in massive screening study
Knowledge-focused CompletedThis study screened up to 1,000 people with severe allergic conditions—like anaphylaxis, eczema, and asthma—along with their relatives to find genetic causes. Researchers collected blood samples and medical history to link specific gene mutations to these diseases. No treatment w…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can wearables decode the mystery of fatigue?
Knowledge-focused CompletedResearchers are using wearable sensors and smartphone check-ins to track fatigue as it happens in people with myeloma, long COVID, heart failure, and healthy controls. Participants wear an ECG patch and a wrist sensor that measure heart rate, activity, and posture, and they rate …
Sponsor: University of Aberdeen • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Family secrets? study maps how relatives talk about genetic health risks
Knowledge-focused CompletedThis study explored how family members share health information about genetic diseases like sickle cell, diabetes, and cancer. Over 1,000 adults completed surveys or interviews about their family health history and support. The goal was to understand social and relational factors…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can a 3-Minute video help cancer patients understand radiation better than a Doctor's talk?
Knowledge-focused CompletedThis study tests whether a 3.5-minute educational video shown before a doctor's visit helps cancer patients understand radiation therapy better than standard verbal instructions alone. One hundred patients scheduled for radiation will be randomly assigned to receive either the vi…
Sponsor: Jinnah Postgraduate Medical Centre • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Can a cancer drug curb severe bleeding in a rare genetic disorder?
Knowledge-focused CompletedThis study looks back at the medical records of 244 adults in France with hereditary hemorrhagic telangiectasia (HHT), also called Rendu-Osler disease, who were treated with the drug bevacizumab. The goal is to describe how the drug was used and to measure its impact on bleeding,…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Your Child's genes: a new clue in fighting a rare cancer?
Knowledge-focused CompletedThis study looks at whether natural variations in immune-related genes affect how well children with a rare type of lymphoma (ALCL) respond to treatment. By analyzing blood samples from 185 patients, researchers hope to find genetic markers linked to longer periods without the di…
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Blood test may spare cancer patients unneeded iron infusions
Knowledge-focused CompletedThis trial explores whether a blood test measuring reticulocyte hemoglobin content (RET-He) can predict how well cancer patients with anemia will respond to intravenous iron treatment. The study involves adults with solid tumors who have functional iron deficiency. By checking RE…
Sponsor: Institut Cancerologie de l'Ouest • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can tracking severe asthma over time unlock better treatments?
Knowledge-focused CompletedThis research program aims to deepen understanding of severe asthma by closely studying its clinical and biological features over time. Researchers will follow more than a thousand people with asthma, aged 6 and older, measuring lung function and tracking how often severe asthma …
Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can a phone call help cancer survivors get the genetic answers they need?
Knowledge-focused CompletedThis study looked at whether offering genetic counseling by phone or video could help more childhood cancer survivors get genetic testing. About 391 survivors took part, comparing remote counseling to usual care. The goal was to see if remote services increase testing uptake and …
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can Real-World data unlock clues to a deadly Post-Transplant complication?
Knowledge-focused CompletedThis study looks back at medical records of children and adults who developed a serious blood-clotting condition called thrombotic microangiopathy (TMA) within a year after a stem cell transplant. Researchers aim to understand survival rates and causes of death in these patients,…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Can a closer look at bone complications in multiple myeloma improve rehabilitation?
Knowledge-focused CompletedMultiple myeloma, a common blood cancer, often causes bone lesions that lead to pain, fractures, and other serious events. This study reviews medical records of patients diagnosed between 2019 and 2021 to describe how often these bone complications occur and what rehabilitation s…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Can Eye-Tracking reveal hidden brain risks in babies with sickle cell disease?
Knowledge-focused CompletedSickle cell disease can affect brain development even in very young children. This study uses eye-tracking—a simple, non-invasive method—to measure attention and processing speed in infants aged 6 to 24 months. The goal is to identify those at highest risk for cognitive challenge…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Fine-Tuning MRI scanners to sharpen the picture of the brain
Knowledge-focused CompletedThis study uses a research-dedicated 3T MRI scanner to develop and optimize imaging protocols in healthy adults. Researchers aim to reduce image distortions, improve contrast and resolution, and create new sequences for functional MRI. The work will help enable future studies in …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
New dashboard aims to make leukemia trials more inclusive
Knowledge-focused CompletedThis study tests a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) designed to help doctors see how diverse their clinical trial enrollments are. The goal is to overcome racial and ethnic disparities in leukemia trial participation. The study enroll…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Blood-Clotting showdown: which device best guides bleeding care in High-Risk patients?
Knowledge-focused CompletedThis study compares three devices that measure how well blood clots — ClotPro, ROTEM, and TEG — in patients undergoing liver surgery, neurosurgery, or cesarean section. The goal is to see how closely the results from these devices agree with each other. The findings may help doct…
Sponsor: Medical University of Vienna • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Exosomes: the decoy receptors that may sabotage lymphoma treatment
Knowledge-focused CompletedThis study investigates why some aggressive B-cell lymphomas stop responding to immunotherapy. Researchers are looking at tiny particles called exosomes that are released by tumor cells and may act as decoys, soaking up therapeutic antibodies before they can reach the cancer. By …
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Beyond breathing: could an asthma drug lift emotional burdens for patients and partners?
Knowledge-focused CompletedThis study looks at how mepolizumab (Nucala), a treatment for severe eosinophilic asthma, impacts emotions and mental well-being in patients and their partners. Researchers will track changes in feelings like anxiety, depression, and stress using questionnaires and interviews. Th…
Sponsor: University Hospital Southampton NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Scientists hunt for genetic roots of rare childhood blood disorder
Knowledge-focused CompletedThis study investigates the genetic causes of pediatric Evans syndrome, a rare autoimmune condition where the immune system attacks blood cells. Researchers analyze blood samples from affected children and their families to find known or new mutations. The goal is to better under…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Malaria's next threat: drug-resistant parasites spread even after treatment
Knowledge-focused CompletedThis study looked at whether malaria parasites that are resistant to artemisinin drugs spread more easily after standard treatment. Researchers treated 160 people in Uganda who had malaria with either artemether-lumefantrine or dihydroartemisinin-piperaquine. They then used mosqu…
Phase 4 • Sponsor: Infectious Diseases Research Collaboration, Uganda • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Can we predict dangerous blood clots in lymphoma patients? a major study aims to find out
Knowledge-focused CompletedThis study looks at how well existing risk models predict dangerous blood clots in people with diffuse large B-cell lymphoma (DLBCL), a common type of blood cancer. Researchers will review medical records from over 1,500 patients across multiple hospitals to see which factors are…
Sponsor: Fondazione IRCCS San Gerardo dei Tintori • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can genes predict liver damage from childhood cancer drugs?
Knowledge-focused CompletedThis study investigates whether certain genetic differences make children with nephroblastoma (kidney cancer) or acute lymphoblastic leukemia (blood cancer) more likely to develop a serious liver condition called hepatic veno-occlusive disease (VOD) during chemotherapy. Researche…
Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Real-World study tracks Poteligeo's impact on rare skin cancer symptoms
Knowledge-focused CompletedThis completed observational study followed 73 adults with mycosis fungoides or Sézary syndrome who were starting treatment with Poteligeo. Researchers tracked changes in symptoms like itching, skin pain, and fatigue, as well as quality of life for patients and their caregivers. …
Sponsor: Kyowa Kirin Pharmaceutical Development Ltd • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New algorithm aims to speed up diagnosis of mysterious high white blood cell counts
Knowledge-focused CompletedThis study tested a decision algorithm to help doctors diagnose the cause of eosinophilia (high levels of a type of white blood cell). The algorithm guides which tests to do and in what order. Researchers enrolled 53 patients and measured how many followed the algorithm correctly…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Gut bacteria may hold key to chemo side effects
Knowledge-focused CompletedThis study looked at how chemotherapy affects the gut microbiome in 40 people with non-Hodgkin's lymphoma. Researchers collected stool samples to analyze changes in gut bacteria after treatment. The goal was to better understand why chemotherapy causes digestive problems like dia…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Could a pneumonia drug boost leukemia treatment? small trial explores safety and dosing
Knowledge-focused CompletedThis early-phase trial tested whether adding atovaquone (a drug usually used to prevent pneumonia) to standard chemotherapy is safe and reaches effective levels in the blood. It involved 26 children and young adults (ages 1 month to 21 years) newly diagnosed with acute myeloid le…
Early phase 1 • Sponsor: Baylor College of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Are sickle cell patients becoming addicted to pain relief? new study investigates
Knowledge-focused CompletedThis completed observational study looked at how often young people with sickle cell disease (under 26) in France develop problematic use of painkillers and a gas mixture called EMONO. Researchers interviewed over 1,000 patients by phone to check for signs of addiction or depende…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
No treatment, just observation: large study looks at PNH blood cells
Knowledge-focused CompletedThis completed study looked at red and white blood cells in people with a rare blood disorder called PNH who also have bone marrow failure. Over 5,500 participants aged 10 and older with aplastic anemia or related conditions provided blood samples. The goal was simply to learn mo…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to unlock the secrets of Children's rare blood diseases
Knowledge-focused CompletedThis study follows children in France diagnosed with severe autoimmune cytopenia—conditions where the immune system attacks blood cells. Researchers will track their health over time to see who achieves remission and what factors influence their recovery. The goal is to better un…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple blood test predict who will get chronic ITP?
Knowledge-focused CompletedThis completed study looked at blood samples from 70 children and adults newly diagnosed with immune thrombocytopenic purpura (ITP), a condition that causes easy bruising and bleeding. Researchers wanted to see if certain immune and blood markers could predict whether the disease…
Phase 3 • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can scans and blood predict CAR T-Cell success?
Knowledge-focused CompletedThis pilot study looked at whether special scans (18FDG PET-CT) and blood tests could help predict how well CAR T-cell therapy works for people with hard-to-treat non-Hodgkin's lymphoma. Twenty patients were followed for up to a year after treatment. The goal was to see if these …
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study examines artery complications in child liver transplants
Knowledge-focused CompletedThis study looked at 583 children who had liver transplants and later developed narrowing or blockage of the liver artery. Researchers wanted to find out how common these problems are and what treatments work best. The goal is to improve care and outcomes for future patients.
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Transplant vs. standard care: which protects sickle cell Kids' brains better Long-Term?
Knowledge-focused CompletedThis study followed 67 children with sickle cell disease who had a high risk of stroke. Researchers compared those who received a bone marrow transplant to those who got standard care, checking brain scans and thinking skills 9-10 years later. The goal was to see which approach b…
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
AI-Powered imaging could revolutionize anemia diagnosis
Knowledge-focused CompletedThis study tested a new way to analyze red blood cells in people with anemia using flow imaging and artificial intelligence. Instead of the usual method of spreading blood on a slide and staining it, the researchers used a machine that takes pictures of cells flowing in liquid. T…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could natural immune cells help fight leukemia drug resistance?
Knowledge-focused CompletedThis completed study from France examined whether a specific type of immune cell (innate CD8+ T cells) is linked to how quickly resistance mutations develop in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Researchers analyzed blood…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks how CAR-T patients feel in real life
Knowledge-focused CompletedThis study looked at 170 patients with aggressive B-cell lymphoma who received CAR-T cell therapy. Researchers used surveys to track how patients felt about their fatigue, symptoms, and daily functioning over time. The goal was to understand the real-world impact of the treatment…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Could a common virus be behind rashes in blood cancer patients?
Knowledge-focused CompletedThis study looked for a virus called HHV6 in the skin and blood of 37 adults with blood cancers who developed a rash during hospital stays. The goal was to see if the virus is linked to the rash, which could help doctors diagnose and treat the rash more effectively. The study is …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Scientists hunt for hidden genes behind common bleeding disorder
Knowledge-focused CompletedThis study examined the DNA of 254 people to find genetic changes that might explain why some individuals have mildly low levels of von Willebrand factor, a protein important for blood clotting. Researchers used whole-exome sequencing to look for variants in known and new genes. …
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Which drug works better for stem cell collection? study compares zarzio and granocyte
Knowledge-focused CompletedThis completed study looked at 70 patients with myeloma or lymphoma who needed stem cell transplants. Researchers compared two drugs, Zarzio and Granocyte, used to stimulate stem cell production before collection. The goal was to see if one drug led to better stem cell grafts. Si…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Study probes link between transfusions and gut trouble in preterm infants
Knowledge-focused CompletedThis completed study looked at 324 extremely low birth weight preterm infants (≤1250 grams) to see how anemia and red blood cell transfusions affect oxygen levels in their digestive tract. Researchers used a non-invasive device to measure tissue oxygen and collected blood, urine,…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Bone loss in hemophilia: new study measures the hidden risk
Knowledge-focused CompletedThis study looked at bone density in 448 men with hemophilia and healthy volunteers to see how common bone loss is. Participants had a bone density scan and some gave blood samples. The goal was to understand if hemophilia itself, not just lack of activity, leads to weaker bones.
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Hidden danger: why some patients can't shake COVID-19
Knowledge-focused CompletedThis study tracked 204 patients with blood cancers or those on certain immune-suppressing treatments to see how often COVID-19 infection persists for 21 days or more. Researchers also looked for factors that make a long infection more likely. The goal was to better understand who…
Sponsor: Maddalena Giannella • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Scientists dig into DNA to unravel blood clot mysteries in rare disorder
Knowledge-focused CompletedThis study looks at people with a rare inherited condition called dysfibrinogenemia, which affects how blood clots form. Researchers collected blood samples from 70 patients to analyze clot structure and search for genetic variations that might explain why some patients bleed whi…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New study tracks immune cell function after stem cell transplants to personalize care
Knowledge-focused CompletedThis completed study looked at how immune cells recover in 61 adults who received a stem cell transplant for blood cancers. Researchers measured the function of T and NK cells by testing their cytokine profiles after stimulation. The goal was to see if these measurements could he…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Rare bleeding disorder study seeks to unlock antibody mystery
Knowledge-focused CompletedThis study looked at 28 people with Glanzmann thrombasthenia, a rare bleeding disorder, to understand why some develop harmful antibodies after blood transfusions or pregnancy. Researchers checked for antibodies every six months and after each transfusion over 18 months. The goal…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New study reveals how well COVID vaccines protect myeloma patients
Knowledge-focused CompletedThis study monitored 201 people with multiple myeloma to see how well COVID-19 vaccines and boosters work for them. Since their immune systems are weaker, researchers wanted to learn if vaccines still provide good protection. The goal was to find better ways to keep this vulnerab…
Sponsor: ASH Research Collaborative • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New program aims to break down barriers to cancer trial participation
Knowledge-focused CompletedThis pilot study tested a program called GUIDE, which uses a trained navigator to help cancer patients overcome social and financial barriers to joining clinical trials. The study included 100 adults with cancer who were eligible for a trial and had at least one health-related so…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
C-Section bleeding study: does tranexamic acid help clotting?
Knowledge-focused CompletedThis study examined how the drug tranexamic acid (TXA) affects blood clotting in women having planned C-sections. Researchers measured clot breakdown times in 34 participants to see if TXA could help prevent heavy bleeding after delivery. The goal was to better understand how TXA…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Blood cell study may personalize asthma and sinusitis treatment
Knowledge-focused CompletedThis study looked at different types of immune cells (eosinophils) in the blood of people with asthma, chronic sinusitis with nasal polyps, or both, compared to healthy volunteers. The goal was to find patterns that could help doctors choose the best targeted therapy for each pat…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Lupus clue: can a heart drug reveal hidden disease markers?
Knowledge-focused CompletedThis small pilot study looked at whether clopidogrel, a drug that stops blood clots, could lower a substance called sCD40L in people with lupus. Lupus is an autoimmune disease where the body attacks itself. The study involved 18 adults with lupus and measured sCD40L levels in the…
Phase 1/2 • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Could your diet trigger lupus? new study investigates
Knowledge-focused CompletedThis study measured phytoestrogens (plant-based compounds) in the blood and urine of 63 premenopausal women with active lupus, other autoimmune diseases, or no disease. Researchers also asked about diet and measured estradiol levels. The goal was to see if these dietary compounds…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New surgical clip tool tested in 161 patients
Knowledge-focused CompletedThis study looked at a new device called AE05ML that helps surgeons place clips on blood vessels and other tissues during keyhole surgery. The goal was to see if the device is safe and works well. A total of 161 adults took part in the study.
Sponsor: Teleflex • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Leukemia Patients' hidden threat: fungal infections under microscope
Knowledge-focused CompletedThis study observed 150 adults with a specific type of leukemia (Ph-negative ALL) to see how many developed serious fungal infections during their first weeks of chemotherapy. Researchers tracked infection rates and deaths linked to these infections. The goal was to better unders…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Antibiotic side effects under the microscope in bone infection study
Knowledge-focused CompletedThis completed study followed 73 adults with bone or joint infections who needed antibiotics for at least 6 weeks. Researchers tracked how often side effects occurred, how severe they were, and whether they affected quality of life. The goal was to understand why some patients st…
Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists probe the hidden types of severe childhood asthma
Knowledge-focused CompletedThis completed study looked at 54 children with severe asthma to better understand the different biological features (endotypes) of the disease. Researchers collected blood, saliva, and nasal samples, along with lung samples from bronchoscopies, to analyze immune cells, metabolis…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Which iron pill works best? small study tests natural vs. standard supplements
Knowledge-focused CompletedThis completed study looked at how well healthy pre-menopausal women with low iron stores absorb iron from two different supplements: Spatone (a natural iron-rich water) and ferrous sulphate (a standard iron pill). Fourteen women took three different doses (5, 10, and 15 mg) of e…
Sponsor: King's College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Lower platelet transfusion threshold safe for central line placement, study suggests
Knowledge-focused CompletedThis study looked at whether it is safe to lower the number of platelets needed before placing a central line (a special IV) in patients with blood disorders. Normally, patients get a platelet transfusion if their count is below 50, but this study tested a lower trigger of 10. Th…
Sponsor: Thomas Kander • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can a simple ultrasound spot hidden liver danger in immune disorder patients?
Knowledge-focused CompletedThis study looked at whether ultrasound and stiffness measurements of the liver and spleen can predict a serious condition called portal hypertension in people with common variable immunodeficiency (CVID). Researchers examined 250 CVID patients during routine visits, using non-in…
Sponsor: University Hospital Freiburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Sickle cell drug safety in pregnancy: small study completed
Knowledge-focused CompletedThis completed study monitored pregnancy and infant outcomes in 13 women with sickle cell disease who were treated with the drug crizanlizumab (Adakveo) during pregnancy or shortly before. The goal was to track rates of fetal loss and birth defects. Because it was a small observa…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
VR rollercoasters vs. beach meditations: which changes your blood more?
Knowledge-focused CompletedThis study looked at how watching relaxing or stressful virtual reality (VR) content changes stress-related substances in the blood of 30 healthy adults. Participants watched a beach meditation or a rollercoaster ride for about 5 minutes, and blood was taken before and after. The…
Sponsor: Van Creveldkliniek • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Are hidden immune defects causing your recurring infections? new study investigates.
Knowledge-focused CompletedThis study looked for hidden immune system problems in adults who get frequent or severe bacterial infections, like pneumonia or meningitis. Researchers screened 120 adults aged 18-65 to see how many had an undiagnosed primary immunodeficiency. The goal was to find out if these c…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for clues to why immunotherapy fails in most patients
Knowledge-focused CompletedThis study looked at 135 people with advanced lung cancer, lymphoma, or other tumors treated with immunotherapy drugs called checkpoint inhibitors. Researchers collected blood and tumor samples over time to measure immune cells and molecules that might predict whether the treatme…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for hidden signs in blood cancers to personalize treatment
Knowledge-focused CompletedThis study collected blood, bone marrow, skin, and cheek cell samples from 650 adults with acute leukemia, myelodysplastic syndromes, or myeloproliferative disorders. Researchers analyzed the samples to find genetic, epigenetic, and drug sensitivity patterns that might predict ho…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New test and tiny particles could help manage bleeding in liver disease
Knowledge-focused CompletedThis study looked at how blood clots in people with liver cirrhosis, a condition that can cause bleeding problems. Researchers used a special machine called T-TAS to measure clotting in blood samples from 60 patients. They also tested whether tiny particles that act like platelet…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Iron deficiency in cancer: a hidden problem exposed
Knowledge-focused CompletedThis study looked at how common iron deficiency is in cancer patients starting chemotherapy. Researchers checked iron levels in 480 adults with solid tumors or lymphoma. The goal was to find out how many patients might benefit from iron injections, without using other drugs like …
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Malaria drug resistance confirmed in ethiopia: study raises alarm
Knowledge-focused CompletedThis study looked at whether the malaria parasite in Ethiopia is becoming resistant to artemisinin, the main drug used to treat it. Researchers tested 277 patients across five sites, checking if parasites were still in the blood three days after treatment and looking for a specif…
Sponsor: Didier Menard • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Blood test could predict leukemia survival
Knowledge-focused CompletedThis study tests whether measuring two substances in the blood—FLT3L and IL-6—during chemotherapy can help predict survival in people with acute myeloid leukemia (AML). Researchers will track 201 newly diagnosed AML patients across 25 French hospitals. The goal is to confirm that…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Personalized medicine for kids with tough cancers: genetic profiling may point to better treatments
Knowledge-focused CompletedThis study looked at whether analyzing the DNA and RNA of children's relapsed or treatment-resistant tumors can help doctors pick targeted therapies. Researchers profiled tumors from 791 children and adolescents using advanced genetic sequencing. The goal was to see how many pati…
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Twin pregnancy complication may affect Kids' hearts and metabolism years later
Knowledge-focused CompletedThis study followed 179 children aged 4 to 16 who were born from twin pregnancies complicated by twin-to-twin transfusion syndrome (TTTS). Researchers checked their heart function, blood pressure, kidney health, and blood sugar control to see if the condition during pregnancy cau…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New screening method may catch kidney problems earlier in sickle cell patients
Knowledge-focused CompletedThis study looked at whether a special kidney scan (scintigraphy) can find early kidney damage in children and young adults with sickle cell disease better than standard tests. 18 patients were checked during their annual visit. The goal is to catch kidney problems sooner so trea…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Study sheds light on mysterious low white blood cell condition in kids
Knowledge-focused CompletedThis study looked back at medical records of 150 children who have a genetic trait called Duffy-null, which is linked to naturally low levels of a type of white blood cell (neutrophils). The goal was to find out how many of these children also have an immune system that attacks t…
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Iron pills may boost vaccine power in pregnancy, study hints
Knowledge-focused CompletedThis study looked at whether iron supplements improve how well vaccines work in pregnant women with anemia (low iron). Researchers compared their immune responses to tetanus, diphtheria, and COVID-19 vaccines against women without anemia. The goal was to see if correcting iron de…
Sponsor: University of Oxford • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Study sheds light on hidden cause of unexplained bleeding
Knowledge-focused CompletedThis study looked at 166 people with unexplained bleeding to find out how many have problems with tiny granules inside their platelets. These granules help blood clot. The researchers measured granule number, content, and release, and checked if these defects were linked to bleed…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New tests could help spot hidden blood disorder in seniors
Knowledge-focused CompletedThis study followed 37 adults over age 60 with unexplained low platelet counts to see if certain tests could predict immune thrombocytopenic purpura (ITP). Participants had blood tests, bone marrow biopsies, and a short course of the steroid prednisone. The goal was to find which…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Trial or standard care? study reveals emotional toll on cancer patients
Knowledge-focused CompletedThis study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Scientists hunt for hidden genes behind rare childhood disease
Knowledge-focused CompletedThis study looked for new genes that cause a rare condition called syndromic congenital neutropenia, where children are born with low infection-fighting white blood cells and other developmental issues. Researchers used advanced gene sequencing on 25 participants to find the gene…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New tool could help stop malaria spread by reading Parasite's mind
Knowledge-focused CompletedThis completed study of 458 people in Burkina Faso aims to develop a tool that estimates how often malaria parasites switch to a form that can spread to mosquitoes. Researchers will measure certain biomarkers in blood samples from people with and without malaria symptoms. The goa…
Sponsor: Institute of Tropical Medicine, Belgium • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Pregnancy anemia study: iron pills under the microscope
Knowledge-focused CompletedThis study looked at how well pregnant women with iron deficiency anemia tolerate and stick with oral iron therapy. Researchers tracked side effects and checked if iron levels improved using blood tests. The goal was to better understand how to treat this common condition during …
Sponsor: The Royal Wolverhampton Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Heart ablation may change stroke risk – new study investigates
Knowledge-focused CompletedThis study followed 167 people with atrial fibrillation or flutter who had a catheter ablation procedure. Researchers measured changes in stroke and bleeding risk scores before and 3, 6, and 12 months after ablation. They also compared different monitoring methods, including impl…
Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New program aims to ease financial burden for young cancer survivors
Knowledge-focused CompletedThis study tested a program called FinFit to help adolescent and young adult cancer survivors deal with money problems caused by their illness. Researchers interviewed 16 people from community cancer clinics to design and improve the program. The goal was to figure out the best w…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Child cancer and birth defects: hidden genetic clues?
Knowledge-focused CompletedThis completed study collected information from nearly 1,000 children who had both cancer and developmental abnormalities like birth defects or growth issues. The goal was to find new genetic syndromes that make children more likely to develop cancer. Researchers analyzed blood a…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Scientists test designer immune molecules in autoimmune diseases
Knowledge-focused CompletedThis study looked at whether specially engineered versions of a natural immune protein (IL-2) can selectively boost regulatory T cells, which help calm the immune system. Researchers took blood samples from 67 people with various autoimmune or inflammatory conditions and tested t…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Preterm babies often get extra blood transfusions, study finds
Knowledge-focused CompletedThis study looked at 201 very premature babies born before 31 weeks to see how often they received blood transfusions that went beyond French guidelines. Researchers found that many transfusions were given even when not recommended, possibly due to the babies' fragile health. The…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Scientists watch sepsis damage tiny vessels in real time
Knowledge-focused CompletedThis completed study looked at 30 adults with sepsis to understand how changes in tiny blood vessels (microcirculation) relate to blood clotting problems. Researchers used a special microscope to view blood vessels under the tongue and measured clotting factors. The goal was to s…
Sponsor: Università Politecnica delle Marche • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
French study tracks Real-World use of oral azacitidine for AML in remission
Knowledge-focused CompletedThis completed study collected real-world data from 112 adults in France with acute myeloid leukemia (AML) who were in remission and taking oral azacitidine as maintenance therapy. The goal was to describe patient characteristics, treatment patterns, and outcomes like relapse and…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Heart risks during CAR T-Cell therapy under the microscope
Knowledge-focused CompletedThis study followed 44 adults with leukemia or lymphoma who received CAR T-cell therapy to see how their hearts were affected. Researchers used heart scans, blood tests, and quality-of-life surveys before and after treatment. The goal was to learn how often heart problems occur a…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Scientists probe immune cells behind rare anemia
Knowledge-focused CompletedThis study looked at how certain immune cells, called T cells, behave in people with autoimmune hemolytic anemia, a condition where the body attacks its own red blood cells. Researchers compared blood samples from 27 patients and healthy volunteers to understand the disease bette…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Heart iron levels measured in Transfusion-Dependent patients
Knowledge-focused CompletedThis study measured how often iron builds up in the heart muscle of people who receive many blood transfusions. Researchers used MRI scans to check heart iron levels in 110 patients with thalassemia, sickle cell disease, or myelodysplasia. The goal was to understand how common th…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Scientists study mosquito saliva to predict malaria and dengue risk
Knowledge-focused CompletedThis study looked at how people's immune systems react to proteins in mosquito saliva after being bitten. Researchers exposed 147 healthy adults in Thailand to lab-grown mosquitoes that can carry malaria or dengue. The goal was to find markers in the blood that show how much expo…
Sponsor: University of Oxford • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Lockdown diaries: 1,300 patients reveal hidden health risks
Knowledge-focused CompletedThis study looked at how the COVID-19 lockdown changed the health habits and medical care of 1,343 people with chronic conditions like heart disease, multiple sclerosis, and hemophilia. Researchers used phone surveys to track medication use, lifestyle changes, and access to healt…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Parents test new app to track baby eczema and gut health
Knowledge-focused CompletedThis completed study looked at how well parents of infants with early eczema and parents of healthy infants could use a mobile-friendly platform called OneBiome. The platform gives reports on the baby's gut microbiome and eating patterns. Researchers wanted to see if parents foun…
Sponsor: Danone Asia Pacific Holdings Pte, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
No more needles? AI may spot iron deficiency in kids from photos
Knowledge-focused CompletedThis study gathered information from 250 children aged 6 months to 6 years to develop artificial intelligence that can estimate iron levels from images and videos. The goal is to create a non-invasive way to screen for iron deficiency, replacing blood tests. Parents and doctors a…
Sponsor: Danone Asia Pacific Holdings Pte, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Major MDS study tracks 2,115 patients to unlock disease secrets
Knowledge-focused CompletedThis completed study enrolled over 2,100 people with or suspected of having myelodysplastic syndromes (MDS), a group of blood disorders. Researchers collected medical data, blood, and tissue samples over time to track how the disease develops and progresses. The goal was to creat…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
HIV Patients' CAR T-Cell cancer treatment under the microscope
Knowledge-focused CompletedThis study looked back at 30 people with HIV who received a special cancer treatment called CAR T-cell therapy for certain blood cancers. Researchers collected information from medical records to see what side effects occurred and how the immune system changed over time. The goal…
Sponsor: AIDS Malignancy Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
New study reveals key bleeding risks for patients on Life-Saving Heart-Lung machine
Knowledge-focused CompletedThis study looked at 278 adults on a heart-lung support machine (VA ECMO) to find early warning signs of dangerous bleeding. Researchers collected data on patient health history, treatments, and lab results at the start of support. The goal was to identify factors that increase b…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Carbon fiber braces could ease ankle strain, early study suggests
Knowledge-focused CompletedThis study tested custom carbon fiber ankle braces in 9 healthy adults to see how they change forces across the ankle joint. Researchers varied the brace design and used a computer model to estimate joint contact stress. The goal was to improve the model and understand how brace …
Sponsor: University of Iowa • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Could cancer trick the body into attacking its own platelets?
Knowledge-focused CompletedThis study looked at 33 adults who had both immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets — and cancer. Researchers wanted to see if treating the cancer could also improve ITP. They also investigated whether cancer cells might mimic platel…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
AI and MRI join forces to speed up cancer radiation planning
Knowledge-focused CompletedThis completed study tested whether artificial intelligence and MRI scans could help automate the planning of total marrow irradiation, a type of radiation therapy given before a bone marrow transplant for blood cancers. Researchers aimed to reduce the 10-day planning time and be…
Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Gut health under the microscope: new study targets hidden danger in ICU blood cancer patients
Knowledge-focused CompletedThis completed study looked at how common gut inflammation and leaky gut are in 80 adults with blood cancer who were in intensive care for sepsis or septic shock. Researchers measured two markers—calprotectin in stool and zonulin in blood—to better understand intestinal dysfuncti…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Could tiny particles explain clot danger in kids with leukemia?
Knowledge-focused CompletedThis completed study looked at 24 children with acute lymphoblastic leukemia to see if tiny cell fragments called microparticles contribute to dangerous blood clots during treatment. Researchers collected blood samples to measure these particles and a clotting protein on their su…
Sponsor: CHU de Reims • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
New blood test may reduce bleeding and clotting in life support patients
Knowledge-focused CompletedThis study tested whether a blood test called thromboelastography (TEG) can better guide blood-thinning treatment in 61 patients on ECMO life support. ECMO patients face serious risks from bleeding or clotting, and current monitoring methods are not very reliable. Researchers com…
Sponsor: Damian Ratano • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC